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ABSTRACT OF DISSERTATION
THE DEVELOPMENT OF NOVEL PROTEASOME INHIBITORS FOR THE TREATMENT
OF MULTIPLE MYELOMA AND ALZHEIMER’S DISEASE

Over a decade, proteasome inhibitors (PIs), bortezomib, carfilzomib (Cfz) and

ixazomib, have contributed to a significant improvement in the overall survival for

multiple myeloma (MM) patients. However, the response rate of PI was fairly low,

leaving a huge gap in MM patient care. Given this, mechanistic understanding of PI
resistance is crucial towards developing new therapeutic strategies for
refractory/relapsed MM patients.

In this dissertation work, we found H727 human bronchial carcinoid cells are

inherently resistant to Cfz, yet susceptible to other PIs and inhibitors targeting

upstream components of the ubiquitin-proteasome system (UPS). It indicated H727
cells may serve as a cell line model for de novo Cfz resistance and remains UPS

dependent for survival. To examine the potential link between proteasome catalytic
subunit composition and cellular response to Cfz, we altered the composition of

proteasome catalytic subunits via interferon-γ treatment or siRNA knockdown in

H727 cells. Our results showed alteration in composition of proteasome catalytic
subunits results in sensitization of H727 cells to Cfz. It supported that proteasome

inhibition by alternative PIs may still be a valid therapeutic strategy for patients with
relapsed MM after having received treatment with Cfz. With this in mind, we designed

and synthesized a small library of epoxyketone-based PIs by structural modifications

at the P1′ site. We observed that a Cfz analog, harboring a hydroxyl substituent at its
P1′ position was cytotoxic against cancer cell lines with de novo or acquired resistance
to Cfz. These results suggested that peptide epoxyketones incorporating P1′-targeting
moieties may have the potential to overcome Cfz resistance mechanisms in cells.

The immunoproteasome (IP), an inducible proteasome variant which is

harboring distinct catalytic subunits, LMP2, MECL1 and LMP7 of the proteasome

typically expressed in cells of hematopoietic origin, plays a role in immune response
and is closely linked to inflammatory diseases. It has been reported that the IP is
upregulated in reactive glial cells surrounding amyloid β (Aβ) deposits in brains of
Alzheimer’s disease (AD) patients and AD animal models.

To investigate whether the IP is involved in the pathogenesis of AD, we

examined the impact of IP inhibition on cognitive function in AD mouse models. We

observed that YU102, an epoxyketone peptide targeting the IP catalytic subunit LMP2,
improved cognitive dysfunction in AD mice without clearance of Aβ deposition or tau
aggregation. Our cell line model study also showed a potential mode of action of

YU102 which is suppressing pro-inflammatory cytokine production in microglial cells.

It suggested that LMP2 contributes to microglia-mediated inflammatory response.
These findings supported that LMP2 may offers a valuable therapeutic target for
treatment of Alzheimer’s disease, expanding the therapeutic potential of the LMP2targeting strategy.
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CHAPTER 1. INTRODUCTION
1.1 The Ubiquitin-Proteasome System (UPS)

The highly regulated degradation of cellular proteins is significantly crucial for

cells to proliferate and differentiate. Before the discovery of the ubiquitinproteasome system (UPS), cellular protein degradation was thought to highly rely on

lysosomes which were discovered by Christian de Duve in 1949 [1]. In 1977, Alfred
Goldberg suggested the presence of another intracellular degradation mechanism in

cells and Goldknopf and Busch identified an ubiquitin, a small protein with 76 amino
acids, but the function was not defined [2]. In the same period, the 1970’s and 1980’s,

Aaron Chiechanover, Avram Hershko, and Irwin Rose also worked on how cells

degrade or destroy the proteins that are not useful anymore, which finally resulted in
discovery and characterization of the ATP-dependent, ubiquitin-mediated protein

degradation system [3-5]. The fundamental importance of the UPS in protein

degradation mechanisms was highlighted when Rose, Hershko, and Ciechanover

were awarded the 2004 Nobel Prize in Chemistry for their contributions in that field,
the discovery of both ubiquitin and the proteasome [6].

The UPS, they found, is responsible for the degradation of ~80% of

intracellular proteins [7]. Protein degradation by the UPS is mediated by the covalent
conjugation of ubiquitin [8]. Protein substrates, destined to be degraded by the UPS,

are labeled with multiple copies of ubiquitin, which are recognized by the proteasome

and initiates their degradation [9] (Figure 1.1). Polyubiquitinated protein is
processed in a stepwise fashion involving a series of three enzymes: Ubiquitin ligase

E1, the ubiquitin activation enzyme, uses ATP hydrolysis to catalyze a thioester bond
between E1 and the glycine residue of ubiquitin. After activation, the ubiquitin is

transferred to the ubiquitin-conjugating enzyme E2. Next, E3 ubiquitin ligase proteins

bind to the protein substrate. Finally, the polyubiquitinated protein is then
1

recognized by the proteasome and degraded [10, 11]. The removal of ubiquitin
monomers or polyubiquitin chains from the substrate protein is catalyzed by

deubiquitinating enzymes (DUBs); these enzymes counter the function of E3
ubiquitin ligases [12]. Over 70 DUBs encoded in the human genome play roles in
recycling of ubiquitin from the substrate proteins, protection from protein
degradation by removing the ubiquitin tags, and also regulation of non-proteasomal
functions such as DNA damage repair [13, 14].

2

Figure 1.1 Ubiquitin Proteasome System
A polyubiquitin chain is covalently linked to a protein substrate through a series of
three enzymes: an E1, an E2, and an E3. This polyubiquitin chain is recognized by the

proteasome, which degrades the protein to short peptides and releases free ubiquitin.

3

1.2 Proteasome Structure and Subtype

1.2.1 Proteasome Structure
As the final executioner of the UPS, the proteasome is responsible for the

controlled degradation of substrate proteins modified with a polyubiquitin chain. The

proteasome is large protein complex, approximately 2.4 MDa, and consisted of two

main components, the 20S core proteasome particle and a 19S regulatory complex.
The 19S regulatory complex harbors 18 subunits containing the components to
remove the polyubiquitin chain for recycling of ubiquitin, unfold the protein, and

control the access of substrate proteins to the proteolytic 20S core [15-19]. The 20S
core itself has a molecular weight of approximately 700 kDa and is formed from four
heptameric rings: two outer α-rings and two inner β-rings (Figure 1.2).

The α-rings made from the α1-α7 subunits play an important role in regulating

substrate entry into the 20S core for proteolysis. The inner two rings are also each
made up of the β1-β7 subunits. The 20S proteasome has three types of catalytically

active subunits, the β1, β2, and β5 subunits located in the two inner beta rings [20].
These catalytically-active subunits utilize an N-terminal threonine residue for their
catalytic activity, placing them in the N-terminal nucleophile hydrolase family. Each
catalytic subunit is initially made with propeptides that protect the N-terminal

threonine residue from acetylation and prevent premature proteolysis [21]. Removal
of these propeptides occurs through an autocatalytic mechanism with the fully

assembled proteasome, indicating that these subunits cannot degrade proteins prior
to their proteasome incorporation [22-26]. When a substrate protein enters the core

20S core particle, the active sites start cleaving the peptide bonds, generating peptide
fragments ~3-22 amino acids in length [27,28]. Most of the products produced by the
proteasome are then hydrolyzed by peptidases to single amino acids [29]. The
4

catalytically-active β1, β2, and β5 subunits also possess distinct substrate specificities.
Structural and mutational studies revealed that the β5-subunit is responsible for

chymotrypsin-like (CT-L) activity and cleaves peptide bonds preferentially after
hydrophobic residues. The β1-subunit has caspase-like (C-L) activity cleaving the

peptide bonds after acidic residues; and β2 cleaves after basic residues, consistent

with trypsin-like (T-L) activity [30-34]. Together, these subunits cleave proteins into
small peptides of unique and diverse sequences, which are especially important for
antigen presentation and immune response [35].

5

Figure 1.2. Structure of the 26S proteasome and the view of subunits of a β-ring
26S proteasome consists of a 20S core particle with two 19S regulatory particles at

either end. The 20S core particle is formed with four heptameric rings, two α-rings
and two β-rings. Each β-ring contains three catalytically-active β-subunits (β1, β2,
and β5).

6

1.2.2 The Immunoproteasome and Thymoproteasome
Apart from the standard or also termed constitutive proteasome, there are

subtypes of proteasomes having different structures: the immune proteasome and

the thymoproteasome. A decade after the constitutive proteasome was discovered,
another major subtype of the proteasome, the immunoproteasome was identified

[36]. The immunoproteasome is predominant in immune cells such as monocytes and
lymphocytes and is dramatically induced in non-immune tissues by proinflammatory

cytokines such as interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) or viral
infection [37]. Whereas the most common subtype of the proteasome, constitutive
proteasome, comprises the catalytic subunits β1(Y, PSMB6), β2(Z, PSMB7), and β5(X,

PSMB5), immunoproteasome differs mainly in incorporation of a distinct set of
additional catalytic subunits in the 20S proteasome. The three catalytic immune
subunits, β1i (LMP2, lower molecular weight protein 2, PSMB9), β2i (MECL-1,

multicatalytic endopeptidase complex-like-1, PSMB10) and β5i (LMP7, PSMB8)

subunits, are the homologues of the β1, β2, and β5 subunits, respectively, with 59-71%
amino acid sequence identity to respective constitutive homologues [38]. The β1i, β2i,
and β5i catalytic subunits are incorporated to 20S proteasomes in place of the β1, β2,
and β5 subunits resulting in formation of the immunoproteasomes (Figure 1.3).

The most recently discovered subtype of the proteasome is the

thymoproteasome. In 2007, Murata et al. identified a previously unrecognized

catalytic subunit called β5t expressed in cortical thymic epithelial cells [39]. The β5t

subunit is the homolog of the β5 subunit with 50% amino acid sequence identity [38].
In cortical thymic epithelial cells, β5t subunit is incorporated with β1i and β2i subunit
forming

the

specific

subtype

of

the

proteasome,

thymoproteasome.

Thymoproteasome plays a role in the positive selection of CD8+ T cells, acting as the
safeguard against mature T cells deriving autoimmune response. Indeed, β5t deficient mice with lacking CD8+ thymocytes were not able to survive by influenza
7

virus infection [40, 41]. However, there is little data to show the exact functions of
thymoproteasome in cancer or in non-cancer disease.

8

Figure 1.3. Catalytic subunit compositions of the constitutive proteasome and
the immunoproteasome
The constitutive proteasome β-ring contains three catalytic β subunits β1, β2, and β5
as well as four catalytically inactive β-subunits. The synthesis of immunoproteasome

is induced by cytokine stimulations such as IFN-γ or TNF-α. The induced

immunoproteasome catalytic subunits β1i, β2i, and β5i are incorporated into the 20S
proteasome to form the 20S immunoproteasome. Catalytic subunits β1/ β1i, β2/ β2i,

or β5/ β5i have caspase-like, trypsin-like, or chymotrypsin-like activity, respectively.
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1.3 Proteasome Function

The life cycle of all proteins starts from the synthesis at ribosomes to their

degradation to peptides and further single amino acids. Protein degradation is the

important step for cellular functions such as protein homeostasis, signal production,
and cell proliferation. The proteasome located in the cytosol and the nucleus degrades

more than 90% of cytosolic proteins by protecting cells from accumulation of harmful

protein aggregates [42]. Proteasomes also play the major role in antigen presentation

by production of peptides with hydrophobic C-terminal amino acids that bind with

high affinity to major histocompatibility class I (MHC-I) receptors on the cell surface
to control immune responses whereas another protease generates the correct N-

terminus [43]. Especially, the immunoproteasome catalytic subunits are known to

produce the peptides with a hydrophobic or basic C-terminal amino acid but less
acidic C-termini [44].

The immunoproteasome, beyond the antigen presentation, regulates oxidative

stress, and cytokine production. The role of the immunoproteasome was defined on

reducing the oxidized proteins under Interferon-induced oxidative stress to maintain
cellular homeostasis [45]. More interestingly, previous studies showing β1i knock out

mice displayed the significantly increase levels of oxidized proteins in the brain and
retinal pigmented epithelial (RPE) cells were more sensitive to oxidative stress in
double knock-out mice of β2i and β5i suggested that immunoproteasome are
protective against oxidative stress and damage [46, 47].

Additional studies of β1i knockout mice showed that their cognitive function

was quite similar comparted to control mice, but they had a higher body weight and
displayed the greater motor function [48-50]. Martin. et al. suggested that the

increased motor function observed in patients with Parkinson’s and Huntington’s

disease may relate to changes in the expression levels of proteasome subunit
expression in the brains of these patients [50]. More recent study showed β5i

knockout altered the levels of cytokines in whole brain and the profiles of microglial
cytokine production without impacting levels of Aβ or amyloid precursor protein
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(APP). Notably, the production of the proinflammation cytokines such as TNF-α, IL-6,
and IL-1β in isolated microglia was significantly reduced in cells lacking β5i [51].

In addition, the immunoproteasome (specifically β5i) has been shown to

modulate pro-inflammatory cytokine production in human tissues (T-cells, B-cells,

neutrophils, monocytes, etc) and thus considered as a promising therapeutic target

for autoimmune diseases [52-57]. β5i/LMP7-selective inhibitors (ONX-0914, KZR616) are currently in early phase clinical development for the treatment of rheumatic

diseases, such as lupus nephritis (LN). For β1i LMP2, there have been a few reports
suggesting its involvement in processing of NF-κB precursors (p100/p105) and

degradation of IκBα [58-60]. However, recent studies dispute the involvement of
LMP2 in inflammatory responses showing using human peripheral blood

mononuclear cells (PBMCs) reported no effect of LMP2 inhibition on cytokine
secretion [56].
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1.4 Development of Proteasome Inhibitors

To elucidate the functions of the proteasome in the cells, proteasome inhibitors

were initially developed but it became evident that proteasome inhibitors may have
therapeutic potential for diseases including cancer and inflammatory disease. Most

of the proteasome inhibitors that have been developed are composed of a peptide

sequence followed by a C-terminal warhead, pharmacophore, which interacts with

the catalytic threonine residues of the proteasome’s active sites. The most of

proteasome inhibitors can be classified by the unique warhead pharmacophore into

five main classes; the peptide aldehydes, peptide boronates, β-lactones, peptide vinyl
sulfones, and peptide epoxyketones (Figure 1.4). In this section, known proteasome
inhibitors classified will be discussed.
1.4.1 Peptide Aldehyde Inhibitors
Peptide aldehydes were the first class of synthetic proteasome inhibitors to be

developed. Since the catalytic activity of the proteasome were initially thought to be

similar to that of serine and cysteine protease, the first type of proteasome inhibitors

were developed by using a C-terminal aldehyde, Z-LLF-CHO, Ac-LLnL-CHO, and Ac-

LLM-CHO [61]. Co-crystallization of a peptide aldehyde inhibitor with the yeast
proteasome showed aldehyde group of the inhibitor binds the active sites of the
proteasome reversibly by producing hemiacetal adducts with the threonine residue

of the catalytic site [30]. While a number of studies have used the peptide aldehyde
inhibitors, further development of this class of proteasome inhibitors has been

limited because of their off-target inhibition of cysteine and serine protease. forming
hemiacetal adducts with their catalytic threonine residues [30, 33]. In this
dissertation work, MG132 (Z-LLL-CHO, shown in Figure 1.4.) was used as a
representative of peptide aldehyde inhibitor.
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1.4.2 Peptide Boronate Inhibitors
Peptide boronates were also initially developted to inhibit serine protease.

However, peptide boronates harbor the high affinity for the active site of the

proteasome by interaction between a boronate hydroxyl group and the N-terminal
amino group of the threonine residue of the proteasome active site. By that means,
peptide boronates can achieve better potency and high selectivity to the proteasome

over the serine protease. In the meantime, Adam et al. reported peptides boronates
such as MG262 which is the boronate analog of MG132 with better potency and higher

selectivity compared to the inhibitors with aldehyde pharmacophore in 1998 [62].

Further medicinal chemistry efforts with peptide boronates led to the development
of the FDA-approved proteasome inhibitor drugs, bortezomib and ixazomib (Figure
1.4). Bortezomib and ixazomib will be discussed in detail below.
1.4.3 β- Lactone Inhibitors

Lactacystin was the first reported natural product of proteasome inhibitor

with a non-peptide backbone (Figure 1.4). In 1995, Fenteany et al. found lactacystin
bound to the threonine residue of the proteasome catalytic β5 subunit. Later, it was

demonstrated lactacystin, converting to active form, clasto-lactacysistin β-lactone, at

pH 8 from inactive itself, irreversibly inhibits CT-L activity predominantly and trpsin-

like (T-L) and Caspase-like (C-L) activities at much slower rates [63]. Although

lactacystin also found to be more specific to proteasome than the peptide aldehyde

inhibitors, later works suggested β- Lactones also bind to some serine proteases [64,
65]. Besides this, the unstability of β- Lactones at neutral pH, and highly complex
synthesis were considered as limitations of β- Lactones. Marizomib, known as

salinosporamide A or NPI-0052, is a second natural product β-lactone, is currently in
clinical development [66]. Notably, Di et al. observed that orally dosed marizomib
significantly reduced the proteasome activity in pre-fontal cortex of healthy
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cynomolgus monkeys, postulating the activity of marizomib to cross the blood-brain
barrier [67].

1.4.4 Peptide Vinyl Sulfone Inhibitors
Peptide vinyl sulfones are another early class of proteasome inhibitors.

Initially, Z-LLL-VS displayed the activity to target all three proteasome catalytic
activities in purified proteasome and in cells. Bogyo et el. showed the vinyl sulfone
pharmacophore binds to the hydroxyl group of the threonine residue, giving rise to
irreversible-binding between proteasome inhibitors to the catalytic residue [68]
(Figure 1.4). In line with this, this class of proteasome inhibitors labeled with a

radioisotope, biotin, or fluorescent groups were utilized to understand the

relationships between the peptide sequence of the inhibitor and its subunit binding
specificities [69-71]. However, since the peptide vinyl sulfones were also initially
developed as cysteine protease inhibitors, the use of vinyl sulfones is limited.
1.4.5 Peptide Epoxyketone Inhibitors
Another important class of natural product proteasome inhibitors,

eponemycin and epoxyketone, was reported in 1999. Both eponemycin and
epoxyketone are consisted of a peptide backbone with and N-acyl group and a C-

terminal α’,β’-epoxyketone moiety (Figure 1.4).

Eponemycin isolated from a

Streptomyces strain was later shown to bind to β1i, β5i and β5 subunits of the

proteasome whereas epoxyketone isolated from a Actinomycete strain was found to
bind to β2, β5, β2i, and β5 by a group under Dr. Craig Crews [72, 73]. Their further

studies showed epoxomicin primarily targets the CT-L acitivity of bovine
proteasomes in an irreversible fashion. In 2000 Groll et al. reported the formation of

a 6-membered morpholino ring between the catalytically active threoine residue and

the inhibitor by X-ray crystallographic study of epoxomicin bound to the proteasome,

giving rise to high specificity for the proteasome over other proteases such as serine
14

and cysteine proteases [74]. However, in 2016, Schrader et al. revealed a 7-membered
1,4- oxazepane ring, instead of a 6-membered morpholino ring between the threonine
residue and the epoxyketone inhibitors using high-resolution X-ray structures of
human 20S proteasome with three different epoxyketone inhibitors [75]. A notable
peptide epoxyketone inhibitor, of special interest, Carfilzomib, is the second
proteasome inhibitor to receive FDA approval for use as an anticancer agent [76].
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Figure 1.4. Representative members of the five major classes of proteasome
inhibitors
A. Peptide aldehydes. A synthetic peptide aldehyde inhibitor MG-132 is shown. B.

Peptide boronates. FDA-approved bortezomib and ixazomib are shown. C. β-lactone.
The natural product lactacystin is shown. D. Peptide vinyl sulfone. Early proteasome

inhibitor Z-LLL-VS is shown. E. Peptide epoxyketones. The natural product
epoxomicin and FDA-approved carfilzomib are shown.
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1.4.6 Subunit-Selective Proteasome Inhibitors
a. β5-selective inhibitors

PR-825 is the β5-seletive peptide expoxyketone inhibitor (Figure 1.5). This

compound was used to distinguish the effects of selective β5-inhibition versus β5i

inhibition on the production of pro-inflammatory cytokines in activated peripheral
blood mononuclear cells (PBMCs) and an animal model of multiple sclerosis [52, 77].

PR-893, also known as CPSI (Constitutive proteasome selective inhibitor), was

another β5-seletive peptide expoxyketone inhibitor. ProCISE assay showed this

compound is highly selective for β5 over β5i (~21 fold) or β1i (~13 fold). PR-893 was
utilized to examine the cellular effect of selective- β5 inhibition in cells, showing that

inhibition of β5 subunit alone was not sufficient to induce cytotoxicity in hematologic
cancer cells. Furthermore, selectively inhibiting β5 with PR-893 did not block
production of IFN-α by bone marrow cells [78, 79].
b. β5i-selective inhibitors

The first β5i-selective inhibitor to be reported was ONX 0914, also referred as

PR-957 (Figure 1.5). The tripeptide epoxyketone ONX 0914 showed a 20- and 40- fold
selectivity for β5i over β1i or β5, respectively in human leukemia cell line MOLT-4

cells. Interestingly, ONX 0914 has shown to block the production of pro-inflammatory
cytokines in PBMCs as well as T-cell activation and differentiation and to attenuate
progression of experimental arthritis in mouse model, indicating a role of β5i during

inflammation [52]. This supports the futher investigations to the potential
therapeutic benefits of β5i inhibitors in treating autoimmune diseases are going [80].
The second β5i-selective epoxyketone inhibitor to be reported was IPSI

(immunoproteasome-selective inhibitor), also known later as PR-924 [79] (Figure

1.5). ProCISE assay showed IPSI was highly potent for β5i (IC50 of 22 nM against β5i)

and 132-fold selectivite for β5i over β5. Later, there were a few studies reporting PR-

924 inhibited cell growth and induce apoptosis in multiple myeloma cells whereas
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PBMCs were not affected and further it exerted antitumor activity in mouse xenograft
models [81].

c. β1i-selective inhibitors

As described above, the peptide epoxyketone natural products eponemycin

and epoxomicin exerted a preference for β1i over other subunits. This gives rise for
our lab to examine the the structure-activity relationship (SAR) for β1i inhibition

using eponemycin analogues. Further medicinal chemistry efforts yielded the first

immunosubunit-selective inhibitor, β1i-selective peptide epoxyketone inhibitor UK

101, to be reported by our group [82] (Figure 1.5). Our group reported UK101 was
more cytotoxic to cancer cells highly expressing β1i than immunosubunit- deficient

cells, suggesting β1i may play a role in regulating cell-growth in cancer cells
abundantly expressing β1i. Later, Wehenkel et al. found that UK101 significantly

reduced tumor growth in a mouse xenograft model of prostate cancer [83]. Later,
UK101 was also reported to be highly selective for β1i over β1 (144-fold), but less
selective for β1i over β5 (10-fold) [84].

Most recently, proteasome activity assay using subunit-selective fluorogenic

peptide substrates showed the previously reported caspase-like inhibitor YU 102
(Ac-GPFL-epoxyketone) had high selectivity for β1i over β5 (> 100 fold) (submitted
data by our group).
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Figure 1.5. Representative of subunit-selective proteasome inhibitors
A. β5-selective inhibitor. The peptide epoxyketone inhibitor PR-825 is shown. B. β5iselective inhibitors. The peptide epoxyketone ONX0914 (PR-957) and IPSI (PR-924)
are shown. C. β1i-selective inhibitor. The epoxyketone inhibitor UK101 is shown.

19

1.5 The FDA-Approved Proteasome Inhibitors for MM

1.5.1 Bortezomib (Velcade®)
The first proteasome inhibitor to receive FDA approval was Bortezomib (Btz),

formerly known as PS-341 and now marketed as Velcade® [85]. Structurally,
bortezomib is a dipeptide boronate, mainly targets the both β5 and β5i subunits

specifically and reversibly [86-88]. It has also been shown to target β1 and β1i with
lower affinity [89, 90].

As previously described in chapter 2.4.1, considerable effort had been put

forth to develop the peptide boronates with the improved selectivity for proteasome

activity over serine proteases, leading to yield the derivatives of peptide boronates

with the dramatically enhanced selectivity for the CT-L activity of the proteasome and
the improved inhibitory potency. Meaningful results from collaboration work

between ProScript and scientists at the National Cancer Institute (NCI) were

published in 1999. The peptide boron ester PS-341 showed the most potent
proteasome inhibition and significant cytotoxicity in the National Cancer Institute

(NCI) panel of 60 cancer cell lines for assessing their anti-cancer activities among 13

derivatives of the peptide boronates. Following these results, PS-341 was tested
against mice bearing tumor xenografts. This study showed that a single i.v. injection
of 0.3 mg/kg PS-341 could significantly inhibit proteasome activity in white blood

cells and in PC-3 tumor cells. Four direct injections of 1 mg/kg PS-341 into PC-3

tumors on a daily or weekly schedule significantly reduced tumor volume as
compared to vehicle [62].

These significant results from preclinical trials of PS-341 led this compound

into clinical trials in 2000 for further investigation of PS-341 as a potential anti-cancer

reagent. Adams et al. reported in phase I trials PS-341 was well tolerated by patients

in general, but with toxicities such as thrombocytopenia, fatigue, and peripheral
neuropathy. Anecdotal reports of efficacy of the PS-341in non-small cell lung cancer,
melanoma, and multiple myeloma were also noted in the study [91]. During its
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clinical development at Millenium Pharmaceuticals, PS-341 received the

nonproprietary name bortezomib and was finally marketed under the brand name
Velcade®. In phase II clinical trials, bortezomib also demonstrated notable anticancer efficacy in newly diagnosed and relapsed/refractory multiple myeloma

patients when administered in combination with other reagents including
thalidomide, dexamethasone, and doxorubicin [92-94].

Based on promising clinical trial results, bortezomib was received the FDA

approval in 2003 for the treatment of relapsed and refractory multiple myeloma [95].

Following the initial approval, the FDA expanded the bortezomib (Velcade) label to
allow for previously untreated patients with multiple myeloma and mantle cell
lymphoma [96, 97].

1.5.2 Carfilzomib (Kyprolis®)
Carfilzomib, formerly called PR-171 and now marketed as Kyprolis®, is the

second proteasome inhibitor to be FDA-approved in 2012 for treating relapsed or
refractory multiple myeloma. In a 2007 publication by Demo et al., carfilzomib

inhibited the CT-L activity of the proteasome more selectively compared to
bortezomib also slightly targeting β1 [86, 98]. Another remarkable difference
between carfilzomib and bortezomib is the proteasome specificity derived from the
unique interaction of the epoxyketone pharmacophore and the N-terminal Threonine

residues of the catalytic subunits of the proteasome. The proteasome specificity led

to lower in vivo toxicity of carfilzomib relative to that of bortezomib and lower
peripheral neuropathy, which is an off-target side effects of bortezomib, in
carfilzomib-treated patients than bortezomib-treated patients [86, 99-103].

Furthermore, in comparison with bortezomib, the irreversible binding mechanism of

the carfilzomib also facilitates a more sustained proteasome inhibition following a

single exposure [86], suggesting carfilzomib exerts enhanced anticancer efficacy over
bortezomib.
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As previously described in chapter 2.4.5, the design of carfilzomib was begun

from the natural product epoxomicin which was found to have proteasome inhibition
in cells [73]. Traditional medicinal chemistry efforts from the Crews lab to optimize

epoxomicin for anticancer activity led to development of potent YU101 derivatives.
Following the successful clinical trials of bortezomib, Proteolix Inc. was established

to develop YU101 as an anticancer therapeutic based on the great potency of YU101.
Further medicinal chemistry efforts at Proteolix resulted in optimization of YU101 to
improve poor water solubility (< 1 µg/mL) of YU101, yielding the lead compound PR-

171, with the modified to the N-cap moiety of YU101 [86]. The potent anti-cancer

efficacy of PR-171 was further verified in mouse xenograft models. Notably, PR-171

exerted its activity in multiple myeloma cell lines and tumor cells derived from
patients who did not respond to bortezomib and cells resistant to conventional
chemotherapeutics.

Based on these promising results of PR-171, Proteolix began phase I clinical

trials of PR-171 with the generic name carfilzomib. Two phases I dose-escalation
trials of single-agent carfilzomib were conducted in patients with relapsed or

refractory hematologic malignancies to determine its safety and efficacy in patients

with hematologic malignancies. Results from these studies established a dosing

schedule of carfilzomib i.v. infusions, a consecutive-day, twice weekly at dose up to

27 mg/m3 [101]. During the two trials, carfilzomib was well tolerated by patients and

the objective response rate (ORR) was 16.7% and the median duration of response

was 7.2 months for the ORR population [100, 101], giving rise to additional phase 2
trials to evaluate the activity of single-agent carfilzomib i.v. infusions at 20 or 27
mg/m3 in patients with relapsed or refractory multiple myeloma patients who did not

respond to prior therapies such as bortezomib and a single immunomodulatory agent
(e.g. thalidomide and lenalidomide). In 2010, Siegel at al. reported the ORR was 24%

and the median duration of response was 7.4 months [104]. In 2009, Onyx
Pharmaceuticals acquired Proteolix for clinical development of carfilzomib and

presented additional safety data from a total of 768 patients treated in phase I and II

studies. Together, carfilzomib was granted accelerated FDA approval on July 20th,
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2012 [76]. From the phase III trial to further confirm the drug’s efficacy and safety,

the clinical benefits of carfilzomib were examined in combination with the

immunomodulatory agent lenalidomide and high-dose dexamethasone in patients

with relapsed and refractory multiple myeloma. Results showed combination

treatment of carfilzomib with the lenalidomide and dexamethasone had superior
activity in comparison to only lenalidomide and dexamethasone, without carfilzomib
[105]. More recently, ENDEAVOR the phase III trial study to compare combination of

carfilzomib and dexamethasone versus that of bortezomib and dexamethasone in

relapsed or refractory multiple myeloma patients, supporting the safety of higher

doses of carfilzomib and better efficacy in those patients: the median progression free
survival (PFS) in the carfilzomib group was 18.7 months, the bortezomib groups
median PFS of 9.4 months [106].
1.5.3 Ixazomib (Ninlaro®)
Ixazomib, previously known as MLN9708 and now marketed as Ninlaro®, is

the third proteasome inhibitor to be received the FDA approval in 2015 for the

treatment of relapse multiple myeloma patients. Ixazomib is the first orally

administered proteasome inhibitor. Structurally, Ixazomib is a N-capped dipeptide
boronate and the boronate pharmacophore. Ixazomib can be formed from the

hydrolized prodrug ixazomib citrate in aqueous solution or plasma, giving rise to the

improved oral bioavailability compared to bortezomib and carfilzomib [107].
Ixazomib has a similar selectivity profile of the proteasome subunit to that of

bortezomib, preferentially inhibiting β5 reversibly, and to a lesser extent, β1 catalytic
subunit [107]. Chauhan et al. also reported that ixazomib inhibited the CT-L activity

more strongly and displayed anticancer activity in multiple myeloma cells, even in
bortezomib resistant multiple myeloma cells. Moreover, ixazomib exerted greater

antitumor efficacy in xenograft mouse models of multiple myeloma, lymphoma, and
solid cancers, supporting ixazomib’s superior anti-cancer activity compared to
bortezomib [107, 108].
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In clinical trials, the median time of progression free survival of patients with

relapsed or refractory myeloma in combination therapy of ixazomib with

dexamethasone and lenalidomide was significantly prolonged (20.6 months in

ixazomib-treated group versus 14.7% in the control group) [109, 110]. Notably,

ixazomib had the improved toxicity profile despite the same pharmacophore as
bortezomib [111]. Taken together, FDA approval was granted to ixazomib in 2015 for
use in combination with dexamethasone and lenalidomide in treating multiple
myeloma in patients who have received at least one prior therapy [112].
1.6 Resistance to Proteasome Inhibitors

As previously discussed, the FDA approvals of proteasome inhibitors,

bortezomib, carfilzomib, and ixazomib in 2003, 2012, and 2015, respectively, have

transformed treatment paradigm for patients with newly diagnosed and refractory

multiple myeloma. However, multiple myeloma remains incurable with an expected

median survival of 7-8 years [113, 114]. The biggest challenge of the use in treatment

of multiple myeloma patients is drug resistance. Although the response rates of

bortezomib and carfilzomib were increased up to ~70-90% when combined with

other drugs including lenalidomide, all patients eventually develop resistance to
therapy and have a dismal prognosis once resistance emerges [115]. In order to
understand the mechanisms of proteasome inhibitor resistance in patients, extensive
preclinical efforts have been undertaken. Although the exact resistance mechanisms

of clinical proteasome inhibitors are still unknown, several preclinical studies
reported the candidate resistant mechanisms to proteasome inhibitors.
1.6.1 Bortezomib resistance
Over the last decade many potential mechanisms, including proteasome-

dependent and proteasome-independent mechanisms, have been studied for
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bortezomib resistance. Mainly reported mechanisms for bortezomib resistance were
mutations in the PSMB5 gene and upregulation of constitutive catalytic subunits.

Using the established bortezomib resistant lurkat cell line model developed by

adapting cells to increasing concentration of bortezomib, Lu et el. and Oerlemans et
al. reported the mechanisms responsible for bortezomib resistance in cancer cells.
The bortezomib resistant- lurkat cell line or -THP-1 cell line containing

overexpressed PSMB5 gene encoding the β5 catalytic subunit of the proteasome.

Moreover, CT-L activity and the expression levels of β5 catalytic subunit were
increased in these cell lines, supporting the β5 catalytic subunit is the key component

for bortezomib resistance [116, 117]. Indeed, siRNA-mediated silencing of the PSMB5

gene resulted in sensitization of bortezomib-resistant THP-1 cells to bortezomib. In
such models, point mutations (Met45, Ala49Thr, and Cys52) in the PSMB5 gene

affecting the proteasomal inhibitory activity of bortezomib were also identified. Since

the location of those point mutations was highly conserved S1 binding pocket of β5,

it was postulated that mutations in the PSMB5 gene interfered the binding of
bortezomib to β5, thus affecting the cytotoxic effects of bortezomib in cells. Although

these preclinical findings suggested the potential bortezomib-resistant mechanism in
several cell line models, only one case study has identified PSMB5 gene mutations in
a patient who had treated with bortezomib [118-120].

Recent study has focused on the potential role of the unfolded protein response

(URP) in resistance to proteasome inhibitors. The UPR is a stress response pathway

and causes cell apoptosis when it is activated. One of main transcription factors

involved in the UPR signaling, X-box binding protein 1 (Xbp-1), is known to be highly

expressed in myelomas compared other cancer types, suggesting Xbp-1 is
indispensable for multiple myeloma pathogenesis such as development of plasma

cells [121, 122]. While it has been reported that proteasome inhibitors can both

induce the UPR and inhibit Xbp-1, the roles of the UPR and Xbp-1 in proteasome

inhibitor resistance was not explored in detail until early 2000’s [123]. In 2012 Ling
et al. reported response of myeloma to bortezomib is correlated to the Xbp-1 and the

study showed the downregulated Xbp-1 expression in bortezomib resistant multiple
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myeloma cells, suggesting low Xbp-1 expression is associated with lower bortezomib
sensitivity [124]. In 2016, Nikesitch also found the significant role of Xbp-1 in

determination of the sensitivity to bortezomib in hematological cell lines and primary

multiple myeloma samples [125]. In contrast to 2012 Ling et al.’s study, Leung-

Hagesteijn et al. found that Xbp-1 silenced mediated bortezomib resistance in

multiple myeloma cell lines and identified two Xbp-1 mutations Xbp-1 L178I and
P326R in bortezomib-resistant multiple myeloma. Multiple myeloma cell lines with
Xbp-1-silenced or Xbp-1 mutations with lower protein load and the UPR activation

may exhibit a survival advantage against proteasome inhibition induced cytotoxicity

[126]. In line with this, high Xbp-1 expression can be a prognostic marker of clinical
outcome in multiple myeloma patients who treated with bortezomib [127]. While

Xbp-1 may play a key role in the sensitivity to multiple myeloma to bortezomib, it is
still unknown whether resistance of other cancer types to PIs are also related to the
function of Xbp-1.

1.6.2 Carfilzomib resistance
The studies conducted to date have mainly focused on elucidating bortezomib

resistant mechanism, and there are only a few have explored resistant mechanisms
against carfilzomib in cancers.

P-glycoprotein (P-gp), also termed as MDR1, is a transporter that extrudes a wide

range of substrates out of the cells in an ATP-dependent manner and it is well

documented that it can mediate cancer resistance to other anti-myeloma agents such
as doxorubicin, paclitaxel, and vincristine [128-131]. Verbrugge et al. found the

several drug efflux transporters have involved in the sensitivities to proteasome
inhibitors such as bortezomib, carfilzomib, ONX 0912, ONX 0914 in carfilzomib/ONX

0914 cross-resistant cancer cells [132]. In this study, overexpression of P-gp was

observed in carfilzomib resistant cells compared to in the its parental cells. Moreover,
the use of reversin 121, a P-gp inhibitor, restored the sensitivity to proteasome

inhibitors in both CEM/VLB cells and peripheral blood mononuclear cells, suggesting
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P-gp plays a significant portion of resistance mechanism in cancers against
epoxyketone proteasome inhibitors. Consistent with these findings, our group also

found that the expression levels of P-gp was upregulated in carfilzomib resistant H23
lung and DLD-1 colon cancer cells and P-gp inhibition by verapamil altered

carfilzomib sensitivity to near that of the parental cell lines [133]. More interestingly,
a 2016 publication showed the induced gene expression of P-gp in primary cells

derived from multiple myeloma patients who did not respond to carfilzomib therapy

[134]. Using multiple myeloma cells isolated from patients during carilzomib therapy,
Besse et al. also showed that ABCB1 gene expression was increased and gene deletion
resulted in sensitization of carfilzomib resistant AMO cells to carfilzomib [135]. Since

only these two studies showed the clinical evidence of P-gp mediated resistance to

proteasome inhibitors, further validations of this mechanism are important to
confirm their relevance in the clinic and to develop the therapeutic strategies
overcoming proteasome inhibitors resistance in cancers.
1.7 Alzheimer’s Disease

Alzheimer’s disease (AD) is the most common form of dementia in the elderly,

accounting for around 60% of all dementia cases [136]. An estimated 5.7 million

Americans of all ages are living with AD in 2018, and the proportion of elderly people

in the population has been increasing steadily, thus the burden of the disease is
expected to become greater over years. AD is a neurodegenerative disorder with a

mean duration of around 8.5 years between clinical symptoms and death.

Alzheimer’s disease was first described by Alois Alzheimer. In 1906, a

psychiatrist and neuropathologist Alois Alzheimer first reported “A severe disease
process of the cerebral cortex” to the 37th Meeting of South-West German

Psychiatrists in Tubingen, Germany. At the meeting, Alzheimer described an unusual
case, a 50-year-old woman Auguste D. with memory impairment, psychosocial
incompetence and disorientation until her death 5 years later. While the unfamiliar
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notion that a “mental” disorder like presenile dementia could be due to “physical”

aberrations was not easily accepted at the time, nevertheless, the disorder would be

named in 1910 after Alois Alzheimer by his mentor, Emil Kraepelin. Alois Alzheimer

also presented the observation of the neuropathological lesions, neurofibrillary

tangles in the brain of her at autopsy in 1911 [137, 138]. Until the late 1960’s,
Alzheimer’s disease itself was not considered as a disease separated from dementia.
Kay et al. identified AD was different from normal aging symptoms in 1964 and it was

reported there was a relationship between cognitive dysfunction and the hallmarks
of the disease such as neurofibrillary tangles and neuropathological lesions in a 1968

publication by Blessed et al. [139, 140]. In 1981, Heston et al. first reported that

relatives of 125 subjects who had autopsy-confirmed AD exhibited a significant

excess of dementing illness consistent with genetic transmission [141]. Later study
also identified mutations involved in hereditary forms of AD in 1996 [142]. These
findings supported AD may be no longer considered as aging but should be diagnosed
differently from other forms of dementia.

According to most sources, AD is defined to consist of irreversible memory

loss, and deterioration of language, judgement, confusion with time or place, and
trouble understanding visual images, progressing over 10 to 15 years. Brain regions,

particularly the neocortex and hippocampus, are associated with higher mental
functions, are most affected by the characteristic pathology of Alzheimer’s disease.

Pathologically, AD is characterized by the accumulation of extracellular amyloid
plaques in senile plaques made by the amyloid-beta protein and intracellular

formation of neurofibrillary tangles which are aggregates of hyperphosphorylated

tau protein, and the loss of neuronal synapses and pyramidal neurons. These changes
develop the typical symptomology of Alzheimer’s disease [143, 144].

Amyloid precursor protein (APP) is cleaved by three types of proteases, α-, β-

and γ-secretases. Amyloid-beta (Aβ) is generated when the APP is cleaved by β

secretase and then by γ secretase complex. β secretase cleaves APP at the bond

between Met671 and Asp672 (β-site) and γ secretase cleaves at the site between 711713 amino acid, resulting in Aβ1-40 or Aβ1-42. Aβ1-42 is mainly found in the amyloid
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plaques, a hallmark of AD, while Aβ1-40 also found in the plaque is predominantly
involved in the brain vessels which is known as cerebral amyloid angiopathy. Since α
secretase cleaves within the Aβ sequence of APP, cleavage of APP by combination of
α secretase and γ secretase does not generate Aβ [145].

Neurofibrillary tangles (NFTs), are aggregates of tau. Tau protein found in

cytosol, axons, and neurons is the member of microtubule-associated proteins family.

Blennow et al. suggested tau proteins might be synthesized in glial cells, mostly in

pathological situations [146]. Microtubule-associated proteins regulates the stability
of axon microtubules by promoting polymerization and binding with tubulin,
resulting in suppression of their dephosphorylation. Phosphorylation of tau can occur

at 30 different sites and hyper-phosphorylation of tau causes self-assemble into

tangles and then accumulation of tau aggregates, thereby, leading the loss of axonal
or dendritic transport in diseases [147-149].

1.8 Causal Theories of Alzheimer’s Disease

Over the past two decades, a considerable research effort has been directed

towards discovering the cause of Alzheimer's disease. To develop safe and effective
pharmacological treatments, it is important to acknowledge that multiple causal

theories for AD have been proposed. A few of these hypotheses are discussed briefly
in this section.

1.8.1 Cholinergic theory
Martorana et al. reported a theory pertaining to the cause of AD, cholinergic

hypothesis based on data showing AD brains expressed lower levels of a

neurotransmitter acetylcholine in the brain compared to non-demented elderly [150].
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Extensive efforts in discovering and characterizing the most important

neurotransmitters and their receptors in the brain underlay specific nervous

connections with brain functions, giving rise to establish the idea that altered function

of neurotransmitter systems was associated with neuropathology. In a 1976
publication, a specific cholinergic deficit was consistently identified from a forebrain
to hippocampus and the cortex from AD patients [151]. Moreover, the activity of

choline acetyltransferase, the enzyme for the synthesis of acetylcholine, was reduced
in pathological samples from the hippocampus and cortex of the patients with AD.

Based on these significant observations, Bartus et al. first stated the cholinergic
hypothesis of age-related cognitive dysfunctions and dementia [152]. In addition, the

1986 Nobel prize was awarded to Rita Levi Montalcini and Stanley Cohen for the

discovery of nerve growth factor, leading the interest of neuronal survival factors in

Alzeheimer’s disease. Taken all together, several drugs targeting cholinergic
transmission were introduced for treatment of AD patients [153]. Four

cholinesterase inhibitors, tacrine, donepezil, rivastigmine and galantamine, have

received approval by FDA and have been widely used for years in many countries, in

particular for patients who were diagnosed with mild and intermediate forms of AD.

Reduction of cholinesterase resulted in retaining acetylcholine in the brain. Though

the therapeutic options available on the market target the cholinergic system, the
strategies have been failed to delay disease progression.
1.8.2 Amyloid theory

Amyloid hypothesis is the most heavily investigated theory for the cause of AD

over 25 years [154-156]. The importance of amyloid was not the prevailed idea in a

field of AD and Alzheimer’s researchers were considering the cholinergic hypothesis

in the 1980s and assumed that a decline in the neurotransmitter acetylcholine is a

cause of the disease at that time. Dennis Selkoe who is now a major proponent of
amyloid hypothesis was not interested in acetylcholine at the time. After he met
George Glenner who initially identified and biochemically characterized Aβ, Selkoe
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moved his research to amyloid field from studying tau protein and built multiple
findings from genetic, molecular, biochemical, and neuropathological studies of

amyloid. Kang et al. reported the discovery of genetic mutations of APP in AD [157].

These mutations in APP/Presenilin are closely linked to the Aβ production process,
providing a rational for the idea that Aβ production and Aβ amyloid fibril formation

represent the central pathogenic cause of AD. In 1992, it was hypothesized by Seiko
et al. that Aβ aggregation was the initiating factor in AD progression since the genetic
links to AD all led to an increase in Aβ protein rather than tangles [158].

While Aβs excised from APP by β- and γ-secretase are released outside the cell and

then are degraded in normal subject, degradation of Aβ is decreased and Aβ peptides
are accumulated in the aged subject. In the brain of normal subject, the concentration
of the Aβ peptide is regulated by following mechanisms: the Aβ peptide generation
from APP, influx into the brain across the blood-brain barrier (BBB), clearance from

the brain, and enzymatic degradation within brain [159-161]. Thereby, impairment

of these regulatory mechanisms could result in the accumulation and deposition of
excessive amounts of the Aβ peptide in the brain of AD patients. This amyloid

hypothesis states that an increase in Aβ aggregation either from decreased clearance

or increased production, leads to microglial and astrocytic activation, altered

neuronal ionic homeostasis, altered kinase and phosphatase activity which increases
phosphorylation of tau leading to tangle formation, leading to neuronal cell death and
neurodegeneration. Thus, drugs that remove the amyloid should slow the
progression of AD. Yet all drugs targeting amyloid, including solanezumab,

bapineuzumab, and gantenerumab, have failed to reduce cognitive dysfunctions in
phase III clinical trials and another antibody, ponezumab also failed after phase II

[162-165]. These results have led scientists to become increasingly skeptical of the

amyloid hypothesis and explore other potential pathogeneses of AD.
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1.8.3 Tau theory
As discussed before, the discovery of neurofibrillary tangles (NFTs) by Alois

Alzheimer in the brains of patients with the neurodegenerative disorder named after

him (Alzeimer’s disease) provided the basis for many studies to elucidate the

molecular, cellular and genetic features of this disease more than a century ago.
However, the discovery that the protein components of NFTs and the paired helical

filaments (PHFs) were hyperphosphorylated forms of tau was achieved only during

the 1980s. In 1986, Kosik et al. discovered that the NFTs in the brains of AD patients
are composed of phosphorylated tau proteins [166]. Microtubule-Associated Protein
Tau (MAPT) stabilizes

microtubules and

can

undergo post-translational

modifications such as phosphorylation. When tau is hyperphosphorylated, it
dissociates from microtubules and aggregates into paired helical filaments (PHFs)

and NFTs. The tau hypothesis speculates that tau tangle pathology precedes Aβ
plaque formation and that tau phosphorylation and aggregation is the primary cause
of neurodegeneration in AD. Tau phosphorylation reduces its ability to promote

assembly of microtubule, giving rise to neurodegeneration through synaptic
disruptions and neuronal loss [167, 168]. Furthermore, the NFT can cause neuronal
impairment and death.

While the amyloid hypothesis suggests that tau aggregation occurs

downstream of Aβ aggregation, tau tangles can be detected in the brains of patients
with very mild dementia and no Aβ pathology [169]. Tau pathology also correlates
more closely with AD progression and severity than Aβ plaque load does [167, 170].
Tau hypothesis-based strategies have shown some promising results and there are

currently seven anti-tau therapies in phase II trials [171]. However, anti-tau therapies
have also failed in phase III clinical trials. Tau phosphorylation was facilitated by a
protein kinase, glycogen synthase kinase 3 beta (GSK-3β), which is an attractive

target for anti-tau therapies. GSK-3β inhibitors are arguably in the most advanced
stages of clinical development for AD. Among the various drugs that are currently

being investigated, tideglusib, an irreversible inhibitor of GSK3-β, has recently
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completed phase II trials yet did not show significant clinical improvement in a phase
II trial [172].

1.8.4 Neuroinflammation theory
Since the late 1980s, several studies have shown that the chronic inflammation,

seen in many diseases of the elderly, was found in the brain of AD patients and may

even to initiate the recognized pathology. In 1990, McGeer et al. reported that

exposure to anti-inflammatory drugs, known as non-steroidal anti-inflammatory

drugs (NSAIDs), lowered the risk of AD. In addition, it was reported that NSAID

delayed the progress of cognitive dysfunctions in 1995, suggesting that inflammation

plays some roles in the disease and targeting inflammation may be used for treatment

of degenerative brain disorder [173, 174]. Furthermore, new hypothesis suggesting
amyloid peptide is involved in immunity also supports the contribution of

inflammation in AD [175, 176]. Additionally, a common risk factor for the disease is

brain injury, suggesting that chronic inflammation could initiate or at least partake in
the course of AD [177].

It has long been thought that the brain was immunologically privileged with

no resident or infiltrating immune cells; however, it is now considered that the cells

of the brain are contributing to neuroinflammatory responses. The glial cells of the
brain (astrocytes, microglia, oligodendrocytes, and pericytes) are involved an

inflammatory response, but the main regulator of inflammation in the brain is the

microglia cell [178]. Microglial cells make up ~12% of brain cells and are generally in

a resting state (termed inactive or less active state). It is now thought that yolk-sac

derived fetal macrophages are the precursors for microglia while originally thought

to be derived from the macrophage cell line. Tumor necrosis factor alpha (TNF-α) or

interferon gamma (IFN-γ) stimulates macrophages to release several pro-

inflammatory cytokines and to produce reactive oxygen species [179-181]. This
proinflammatory state, has high microbicidal activity and is an important defense
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mechanism for the body. However, it also can cause damage to the tissues and it has
been implicated in the development of autoimmune disorders.

While inflammation was typically considered a downstream event to the

amyloid hypothesis, Aβ causes microglia activation, neuroinflammation may worsen
the course of disease. When fully activated, microglial cells produce proinflammatory cytokines including TNF-α, interleukin-6 (1L-6), and interleukin-1β

(IL-1β) [182]. These pro-inflammatory cytokines and activated complement factors

has led to the idea that neuroinflammation is involved in the pathology of Alzheimer’s
disease. Indeed, the activated microglial cells were increased in AD progression,

suggesting that Aβ deposition stimulates microglial activation. Several studies have

shown that microglia can surrounds Aβ plaques and can phagocytose Aβ [183-185].

Microglia can be stimulated by a variety of substances to yield an inflammatory
phenotype in the brain. Induction of a proinflammatory phenotype by LPS or TNF-α

cause Aβ clearance [186, 187]. On the other hand, anti-inflammatory cytokines
induction exacerbated Aβ deposition [188]. In a 2015 publication, a long-term
induction of anti-inflammatory cytokine IL-10 showed a significant increase in Aβ
deposition and led to cognitive behavior in APP transgenic mice model [189]. Thus,

we postulate high levels of these markers can represent progression of AD. Several
clinical anti-inflammatory drugs targeting COX or TNF-α have been investigated for
their effects on AD via population-based studies or randomized controlled clinical
trials, yet have yielded no clinical AD therapies so far [190]. On the other hand, several
compounds that suppress neuroinflammatory responses have been identified from
screening campaigns but not yet translated into effective AD drugs [191, 192].
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1.9 Treatment of Alzheimer’s Disease

To date, the Food and Drug Administration (FDA) and the European Medicines

Agency (EMA) have approved only medications for alleviating symptoms for AD
patients.

These medications include acetylcholinesterase (AChE) inhibitors such as donepezil,

galantamine, rivastigmine, and a NMDA receptor antagonist, memantine. AChE
inhibitors are used to induce the level of acetylcholine at synapses restraining the loss

of neurotransmission found in AD. On the other hand, a NMDA receptor antagonist
regulates glutamate-induced toxicity.

Donepezil hydrochloride (brand name Aricept) approved in 1996 for

treatment of all stages of AD by preventing the breakdown of acetylcholine in the
brain is a highly selective and reversible antagonist for AChE. In a 1998 publication,

Rogers et al. reported the effect of donepezil hydrochloride on 468 participants who

had mild to moderate AD. In this study, 32% of the 5mg treatment group and 38% of
the 10 mg treatment group showed clinical improvement on various psychiatric

scales, indicating donepezil is effective in cognition and global function decline in AD

[193]. So far, donepezil is the only AchE inhibitor approved for treatment of severe
AD.

Rivastigmine tartrate (brand name Exelon) approved in 2000 is less

frequently used than other AChE inhibitors for treatment of mild to moderate AD
patients. Lanctot et al reported the effect of rivastigmine at different dosages and

various treatment intervals. The patients administered at high dose (6-12mg/day)
showed dramatic improvement in cognitive function at all intervals (12, 18, and 26

weeks), proving treatment of rivastigmine at 6-12mg daily over a long time periods
may be an effective strategy [194].

Galantamine hydrobromide (brand name Razadyne) approved in 2001 for

treatment of mild to moderate AD by inhibiting the hydrolysis and increasing the
concentration of acetylcholine. Galantamine is a specific, competitive, and reversible
AChE inhibitor. As described in a 2006 review article by Loy and Schneider et al.,
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treatment of galantamine (18-32 mg/day) showed significant improvement on
cognitive symptoms at 3 months and 6 months intervals [195].

Memantine (brand name Namenda) was approved by FDA in 2003 for

treatment of moderate to severe AD [196]. Memantine is a noncompetitive NMDA

receptor antagonist, blocking glutamatergic receptors and regulates the action of

glutamate. Under physiological conditions, magnesium ions are capable of blocking
NMDA receptor which is a glutamate receptor and ion channel protein found in nerve
cells. Glutamate signaling enhances depolarization of the post-synaptic membrane
and unblock NMDA allowing calcium ions to flow into the postsynaptic neuron. In AD,
however, constantly stimulated glutamate and over-activated NMDA receptor could

be observed, causing cognitive impairment. Thus, memantine is considered as a
neuroprotective agent by preventing excess glutamate-related excitotoxicity [197]. In

a 2003 publication, Reisberg et al. showed memantine regulated NMDA receptors,

leading to alleviation of AD symptoms. Among 345 elderly participants with

moderate to severe AD, 29% of the memantine treated group showed the
improvement of cognitive dysfunctions [198]. Although memantine has shown to
positive results to reduce the rate of cognitive decline, it is not also capable of
preventing the neuronal damage detected in AD.

1.10 Efforts to Develop Alzheimer’s Disease Therapeutics

As we discussed previously, evidence supporting the amyloid theory led to

development of AD therapeutics either disrupting aggregation, or promoting removal

of Aβ. Based on the amyloid theory, Inhibitors targeting Aβ aggregation have been
developed, including glycosaminoglycan 3-amino-1-propaneosulfonic acid (3APS),
colostrinin, scyllo-inositol and Zinc/Copper chelators. Among these compounds, only

3APS designed to interfere with endogenous glycosaminoglycans, which were shown
to promote aggregation of Aβ, has reached to phase III clinical trials, however, results
of the clinical trials were disappointing [199].
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Immunotherapy has been one of the most attractive approaches for AD drug

development. It has been reported that both vaccination and monoclonal antibodies
approaches have been developed to be successful. At the first time, using an active

vaccine (AN1792) with Aβ1-42 showed the promising results only in preclinical studies,
but not in clinical trials with side effect such as encephalitis [200]. Since encephalitis
was found in one patient treated with AN1792 in a Phase I clinical trial who died
approximately one year after her last injection, vaccines have been developed to

improve the safety issue. However, the various types of antibody responses were

found in elderly and it led to further investigation of passive immunization using
monoclonal antibodies.

Bapineuzumab (Janssen/Pfizer) and Solanezumab (Eli Lilly) are monoclonal

antibodies designed to increase the clearance of Aβ and have been heavily
investigated. Bapineuzumab is a humanized, N-terminal specific anti-Aβ monoclonal
antibody, binding to neurotoxic amyloid proteins in the brain. Several preclinical

studies have shown that passive immunotherapy with monoclonal antibodies led to
a significant clearance of Aβ protein levels in the brain and improved the memory loss

in transgenic mouse models with excessive Aβ proteins [201-205]. Additionally,
phase II clinical trials have shown that bapineuzumab can reduce deposition of

amyloid proteins and the concentration of phosphorylated tau proteins in the

cerebrospinal fluid [206, 207]. Based on ongoing Phase II study, Elan/Wyeth

announced the start of the Phase III clinical trials for bapineuzumab on May 2007.
However, bapineuzumab was failed in phase III clinical trials [208]. Solanezumab

developed by Lilly, on the other hand, is a monoclonal antibody that recognizes an

epitope in the core of the amyloid peptide, binding to soluble Aβ and with low affinity
for the fibrillar Aβ form. Solanezumab has also been tested in two phase III clinical
trials (Expedition 1 and 2) in a population of patients with mild to moderate AD

similar to that in trials with bapineuzumab. Unfortunately, it was recently found that

solanezumab also could not meet its clinical endpoints for efficacy in patients with
mild AD [209]. The human monoclonal antibody Aducanumab (Biogen) is another
attractive passive immunization strategy for treatment of AD and has been fast37

tracked to phase III clinical trials. Aducanumab is currently being evaluated in two
global Phase 3 studies (ENGAGE and EMERGE) designed to evaluate its safety and

efficacy in slowing cognitive impairment in people with very early AD or mild AD. This
study is set to end in April 2022.

Considerable efforts to prevent Aβ production have focused on inhibiting β-

secretase, which are responsible for production of Αβ since the proteolytic processing
of APP by β-secretase (beta-site APP cleaving enzyme 1, BACE1) is the rate-limiting

step in the production of Aβ. Thus, BACE1 is thought to be a major therapeutic target

and BACE1 inhibitors have the potential to be disease-modifying drugs for AD
treatment. Due to the location of BACE1 in the brain BACE1 inhibitors need to cross
the BBB to access the target and it is quite challenging [210]. Furthermore, BACE1

displays the large catalytic pocket, suggesting BACE1 inhibitor needs to be large
enough to interact with the active site though the inhibitors also should be small

enough to have drug-like physiochemical properties [211]. Vassar also reported that

several BACE1 inhibitors during the clinical trials showed off-target toxicity,
indicating the inhibitors are also required to be selective over other aspartic
proteases to prevent toxic effects by cross inhibition. With efforts to search for

effective and selective BACE1 inhibitors, some compounds have shown promising
results in preclinical studies and six drugs, JNJ-54861911, CNP520, LY3202626,

elenbecestat, lanabecestat, and verubecestat, are currently being evaluated in clinical

trials in patients with mild to moderate AD [212, 213]. Especially, verubecestat was
the first BACE1 inhibitor to reach to phase III clinical trials. However, Merck has

discontinued its pivotal trial in patients with mild to moderate AD due to low efficacy

in cognitive decline reduction [214]. Consequently, these disappointing results

remain questions regarding the potential use of BACE1 inhibitors as AD drugs.
Nevertheless, recent results from an animal model to mimic BACE1 inhibition in

patients with AD by deletion of BACE1 support that BACE1 inhibition can completely
reduce amyloid pathology and inhibiting BACE1 may have a potential for treatment
of AD [215].
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The large body of results showing tau protein aggregates accumulated in the

brain of AD patients highly led to investigation of therapeutic strategy targeting tau

to treat AD patients. Preclinical studies from the transgenic mouse models using

various anti-tau antibodies have shown that antibodies against tau prevented
extracellular trans-synaptic transmission of misfolded tau between cells. Following
toxicology studies, the compound C2N-8E12, now known as ABBV-8E12 (AbbVie &
C2N Diagnostics), was reached to initiation of clinical trials in 2015. In a phase I
clinical study safety, tolerability and pharmacokinetics of ABBV-BE12 were tested on

32 patients. As a result, ABBV-BE12 was found to be safe and tolerable when single
injected into the blood [216-218]. Positive results from a phase I trial led to phase II

clinical trials of ABBV-BE12 and the study is set to end in May 2019. Another anti-tau

monoclonal antibody BIIB029 (Biogen) was also moved to phase II clinical trials with

the patients with early AD and the estimated study completion date is July 2021 [219,
220].

Azeliragon (vTv Therapeutics Inc), also known as TTP488, is an orally

bioavailable small molecule that inhibits the receptor for advanced glycation end
products (RAGE) that is thought to be involved in the development of Alzheimer’s
disease. RAGE found in the brain and the periphery is an immunoglobulin family

member and is expressed in endothelial cells and microglia cells and is upregulated
in AD [221-224]. In a 2012 publication, Li et al. suggested that RAGE may contribute

to AD pathology by promoting influx of peripheral Aβ into brain and regulating Aβ

induced oxidative stress, mediating AGE induced hyperphosphorylation of tau [225].
RAGE is also thought to interfere with inflammation and transfer Aβ into the brain. A

number of preclinical studies and positive results of phase I/II clinical trials led to
phase III clinical trials of azeliragon to evaluate the efficacy and safety of this

compound in patients with mild Alzheimer's disease. The company vTv Therapeutics,

conducting a phase III trials of the drug in mild AD, announced preliminary results in

early 2018. Unfortunately, the study was terminated due to a lack of efficacy at the 5
mg azeliragon dose [226].
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Lumateperone (Intra-Cellular Therapies Inc), known as ITI-007, is a first-in-

class molecule designed to selectively and simultaneously modulate certain neuronal

pathways. This molecule acts on serotonin, dopamine, and glutamate receptors. It is

an investigational therapy being developed to treat agitation in dementia, including
Alzheimer's disease and mental illness as well as schizophrenia. In 2014, Intra-

Cellular announced the phase I/II clinical trials results that lumateperone was safe
and well-tolerated and showed improved cognitive function and thereby the phase

III clinical trials were initiated in 2016 to evaluate the efficacy and safety of

lumateperone in about 360 people diagnosed with probable Alzheimer’s disease
[227,228]. Lumateperone, however, was not likely to meet its primary endpoint upon
completion and therefore the study was stopped for futility in Dec 2018 [229].
1.11 Proteasome in Alzheimer’s Disease

While years of debate have not provided a conclusive answer to the question of

events related to the proteasome causing to AD pathology, there is growing evidence

showing changes in the UPS have been associated with AD [230-232]. In the early

phase of AD, proteasome activity was decreased, and ubiquitin accumulation found

in plaques and tangles was also associated in late AD [231, 233-236]. Interestingly, it
was reported alterations in the UPS affect the degradation of Aβ in neurons and

astrocytes. In addition, Aβ oligomers downregulated in vitro proteasome activity and
lower proteasome activity was also observed in the several brain areas of AD patients
[237-239]. However, these studies were limited to assess the proteasome activity in
whole brain homogenates or in cell line models, not examining activity and the

expression levels of immunoproteasome in glial cells. While the role of
immunoproteasome in neuroinflammation is not clearly understood, researchers
also observed whether expression and activity of immunoproteasome are involved in

microglial activation in AD patients and in a mouse model of brain injury [240-243].
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In a 2006 publication, Mishto reported that β1i expression was elevated with age, and
in the brain of AD patients [244]. In line with this, Orre et al. showed that activities of
immunoproteasome subunits were increased along with promoted plaque in AD mice
and

patients,

suggesting the tight

correlation between upregulation

of

immunoproteasome and reactive astrocytes and microglial cells derived from
patients with AD [240]. Importantly, most recent study has shown that LMP7/β5i

knockout altered microglial cytokine production profiles and improved cognitive

dysfunctions in a mouse model of Aβ deposition, indicating a potential role of

immunoproteasome in Aβ-induced neuroinflammation [51]. While it becomes clear
that immunoproteasome activity is enhanced in microglia of AD, suggesting the

involvement
therapeutic

of

immunoproteasome

potential

for

AD

in neuroinflammatory

treatment,

it

is

still

responses and

unknown

whether

immunoproteasome selective inhibitors display pharmacological inhibition on AD
pathology.
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CHAPTER 2. HYPOTHESIS AND SPECIFIC AIMS

The overall goal of this research is to develop novel, effective proteasome

inhibitors for treating multiple myeloma patients who do not respond to PI therapies
and Alzheimer’s disease patients.

In order to design new and effective therapeutic strategies to bypass resistance,

it is important to better understand the mechanisms of proteasome inhibitors

resistance. Recently, several studies have shown that UPS-targeting inhibitors retain

anticancer activity in Btz-resistant MM cells, indicating that the UPS remains essential
in these cells [245, 246]. Furthermore, PIs other than Btz remained cytotoxic to Btz-

resistant MM cells [247], suggesting that alternative PIs can overcome Btz resistance.
However, information on the ability of UPS-targeting inhibitors to overcome Cfz

resistance is currently limited. Additionally, it is currently unclear whether the

proteasome is still a valid target in Cfz-resistant cancer cells. To date, investigations
of Cfz resistance have largely focused on acquired resistance due to the Cfz-adapted

cancer cell line models and the availability of clinical samples derived from patients

who have developed resistance after prolonged Cfz therapy. On the other hand,
mechanistic investigations of de novo Cfz resistance have been scarce, due to the lack
of appropriate cell line models and patient samples. We hypothesized that

proteasome function remains vital to the survival of de novo Cfz-resistant cancer cells,

and that targeting the proteasome using alternative proteasome inhibitors is a good
strategy to overcome Cfz resistance.

As described previously, the immunoproteasome known to be involved in

regulation of inflammatory immune responses, is currently investigated as a potential
therapeutic

target

for

autoimmune

diseases

[51,

248].

Likewise,

the

immunoproteasome is also reported to be upregulated in in reactive astrocytes and
microglia isolated from AD patients and AD mouse models [240, 241, 244, 249, 250].
However, the physiological role of immunoproteasome in these AD brains, is still
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completely unknown. Recent study showed LMP7 knockout altered microglial

cytokine production profiles and improved cognitive deficits in a mouse model of Aβ
deposition, indicating a potential role of immunoproteasome in Aβ-induced

neuroinflammation [51]. Interestingly, moderate up-regulation of LMP2 expression

in AD patients was also reported. Despite these data suggesting the involvement of

immunoproteasome in neuroinflammatory responses and therapeutic potential for
AD treatment, the pharmacological inhibition of LMP2 has never been tested for the
impact on AD pathology. With this in mind, we also hypothesize whether LMP2

inhibitors could offer a novel strategy in AD progression via regulation of
inflammation. Our overall study had the following aims:

Aim 1. Determine whether alterations in proteasome catalytic subunit

composition are causally linked with changes in the sensitivity of cancer cells
to Cfz. I initially identified the first de novo Cfz-resistant cancer cell line model.
Proteasome activity and immunoblotting analyses were used to detect changes in

proteasome catalytic subunits. I altered proteasome catalytic subunit compositions
in cancer cell lines using genetic (overexpression & knockdown) and biochemical

(INF-γ) tools and investigated whether those alterations led to changes in
proteasome inhibitor sensitivity in Cfz-resistant cancer cells.

Aim 2. Optimize small molecules that inhibit the growth of Cfz-resistant

cancer cells. I performed cell-based screens of in-house proteasome inhibitor

libraries containing proteasome catalytic subunit-specific inhibitors to identify

compounds that are effective against Cfz-resistant cancer cells. Using selected lead

compounds, I tested their efficacy against primary multiple myeloma cells derived
from patients who are proteasome inhibitor-resistant. To improve the potency of the
lead compound, we utilized a previously reported docking model of the compound to

its targets. Traditional medicinal chemistry was performed to design and synthesize

analogues of the most promising hit compound. Compound analogues were assayed
for in vitro proteasome inhibitory activity and later for their cytotoxic activity in Cfz-

resistant cancer cells.
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Aim 3. Investigate whether LMP2 inhibitor has anti-AD activity via
regulation of inflammation: We assessed animal behavior tests using LPS-induced
inflammatory and transgenic AD mouse models to examine the effects of proteasome

inhibitors on cognitive impairments. ELISA assay, Thioflavin staining of amyloid-beta,
and HEK293-tau-BiFC cells were utilized to investigate the effect of the proteasome

inhibitors on amyloid-beta or tau aggregation, respectively. Membrane cytokine
array and ELISA assay were used to evaluate the effect of the compound on proinflammatory cytokines in microglial cells.
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CHAPTER 3. H727

CELLS

ARE

INTRINSICALLY

RESISTANT

TO

THE

PROTEASOME INHIBITOR CARFILZOMIB, YET REMAIN DEPENDENT ON THE
PROTEASOME FOR CELL SURVIVAL AND GROWTH
The work in this chapter was published in Scientific Reports 2019, 9, 4089 [333].

3.1 Introduction

The proteasome controls numerous cellular processes via the regulated

degradation of proteins. Despite its essential functions, it is now understood that
agents which inhibit the proteasome have therapeutic selectivity for cancer cells as
compared to normal cells. This selectivity likely occurs because rapidly proliferating

cells have greater protein degradation requirements and due to the proteasome’s role
in regulating a variety of critical signaling pathways. In general, 20S proteasomes

were thought to exist in two main types, the constitutive proteasome (cP) and the
immunoproteasome (iP). More recently, various subtypes of proteasomes containing

a non-standard mixture of catalytic subunits have been identified in cancer cell lines.

These so-called intermediate proteasomes differ from both constitutive and
immunoproteasomes, which contain mixed assortments of cP and iP catalytic

subunits, such as β1i-β2-β5i [251-255]. It was further reported that these

intermediate proteasomes may confer differing sensitivities to proteasome inhibitors
(PIs) as compared to cPs or iPs [253, 254, 256]. However, whether intermediate
proteasome subtypes contribute to the resistance of cancer cells to proteasome

inhibitors is currently unknown and the clinical implications of intermediate
proteasomes have yet to be defined.

The clinical and commercial successes of bortezomib (Btz, Velcade®),

carfilzomib (Cfz, Kyprolis®), and ixazomib (Ixz, Ninlaro®) have validated the

proteasome as a valuable target in the treatment of cancer. While the first-in-class
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proteasome inhibitor (PI) drug Btz and the first oral PI Ixz utilize boronic acid

pharmacophores, the second-generation PI Cfz harbors an epoxyketone that
irreversibly inactivates the proteasome with high mechanistic selectivity [257, 258].
This selectivity affords Cfz a reduction in off-target interactions yielding an improved

safety profile over Btz, most notably a reduced incidence of severe peripheral
neuropathy[259]. With positive results from recent phase III clinical trials [260-265],

Cfz is now firmly placed as a mainstay of refractory MM therapy. Nevertheless, a

considerable portion of MM patients are refractory to Cfz or develop resistance after
prolonged Cfz treatment. A meta-analysis of 14 clinical trials found that 44% of
patients could not achieve a minimal response or better [266]. As a monotherapy in

patients with relapsed MM, for example, the response rates for Cfz were in the ranges

of 25-40% [267]. When used in combination with other drugs (often with

dexamethasone and/or lenalidomide), response rates substantially improved, but a

significant subset of non-responders persisted [105,106, 265, 268, 269]. Even for

those who initially respond to Cfz-based therapy, disease eventually relapses with a
median progression-free-survival (PFS) of ~17-26 months [105, 106]. To date,

extensive efforts have been yielding the development of new therapeutics for these

Cfz resistant patients. However, clinical effects of the new therapeutics are
disappointing likely due to a lack of understanding of the biological mechanisms
underlying Cfz resistance.

Mechanistic investigations of Cfz resistance have so far utilized cancer cell lines

adapted to gradually increasing concentrations of Cfz, revealing that the
overexpression

of

P-glycoprotein

(P-gp)

and

mutations

or

amplification/overexpression of proteasome catalytic subunits are largely

responsible for acquired Cfz resistance observed in established cell lines [132, 133].
To date, cell-based models of de novo Cfz resistance are unavailable. Here, we report

for the first time that H727 cells (derived from a human bronchial carcinoid tumor)

are inherently resistant to Cfz, yet remain dependent on the proteasome for their

survival and growth. Our current results suggest that de novo Cfz resistance observed
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in H727 cells may be mediated at the 20S proteasome level, providing previously
unknown insights into the mechanisms of de novo PI resistance.
3.2 Material and Methods

3.2.1

Cell lines and chemicals

Hep3B, Huh7, LCSC, HepG2, and PLC/PRF/5 hepatic cancer cells were a kind gift of

Dr. Roberto Gedaly (College of Medicine, University of Kentucky). MDA-MB-231,
HCC1143, and HCC1937 breast cancer cells were purchased from the Korean Cell Line

Bank (Seoul, Korea). All other established cell lines were obtained from the American

Type Culture Collection (ATCC, Rockville, MD). All cells were cultured according to

the manufacturer’s protocol in 5% CO2 in medium. Cultured cell lines were tested for

Mycoplasma contamination routinely every 6 months. Specifically, H23 and H727
cells were tested three times in the course of performing the experiments described

within this dissertation work. Inhibitors of UPS pathways used in this study were
purchased from commercial vendors: carfilzomib (LC Laboratories, Woburn, MA),

bortezomib (ChemieTek, Indianapolis, IN), MG-132 (EMD Millipore, San Diego, CA),

PYR-41 (ApexBio, Houston, TX), and P5091 (ApexBio, Houston, TX). The following

proteasome fluorogenic substrates were used: Suc-LLVY-AMC (Bachem, Torrance, CA;
I-1395), Ac-WLA-AMC (Boston Biochem, Cambridge, MA; S-330), Ac-nLPnLD-AMC

(Bachem; I-1850), Ac-RLR-AMC (Boston Biochem; S-290), Ac-ANW-AMC (Boston

Biochem; S-320), and Ac-PAL-AMC (Boston Biochem; S-310). Human recombinant
Interferon-γ was purchased from eBioscience (San Diego, CA).
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3.2.2 Cell viability assay
Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation
assay (Promega, Madison, WI) according to the manufacturer’s protocol. Briefly, cells
were seeded at a density of 5,000-10,000 per well in 96-well plates and allowed 24

hours to attach. After cells were treated with the indicated concentrations of

compounds for 72 hours, cell viability was measured using the reagent provided in
the assay kit. Absorbance at 490 nm was measured using a SpectraMax M5 microplate

reader (Molecular Devices, Sunnyvale, CA). Results were analyzed using GraphPad
Prism (La Jolla, CA).

3.2.3 Immunoblotting
Total cell lysates containing equivalent protein content were separated by 12% SDS-

PAGE and transferred to polyvinylidene difluoride membranes (Millipore, Billerica,
MA) via a semi-dry apparatus. Membranes were then blocked in 5% non-fat dry milk

(Bio-Rad, Hercules, CA) in Tris-buffered saline with 0.05% Tween-20 (TBST) for 1 h

at room temperature, followed by incubation with 3% BSA in TBST containing the

respective primary antibodies overnight at 4°C: β1 (Enzo Life Sciences; PW8140), β2

(Enzo Life Sciences; PW8145), β5 (Thermo Scientific; PA1-977), β1i (Abcam; ab3328),

β5i (Abcam; ab3329), β-actin (Novus Biologicals; NB600-501), and β2i (Santa Cruz;
sc-133236; 3% milk-TBST used for dilution). Membranes were then washed five

times with TBST and incubated with HRP (Horse radish peroxidase)-conjugated

secondary antibodies for 1 hour at room temperature. Immunoreactive bands were

visualized using SuperSignal West Femto Chemiluminescent Substrate (Thermo
Scientific, Rockford, IL) and X-ray film (Thermo Scientific or GeneMate).
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3.2.4 Proteasome Activity Assay
Subunit-selective fluorogenic peptide substrates were used to measure the catalytic
activities of individual catalytic subunits by monitoring the rate of substrate

hydrolysis over time. Briefly, protein lysates were prepared using passive lysis buffer
(Promega, Madison, WI) and diluted in 20S proteasome assay buffer (20 mM Tris-HCl,

0.5 mM EDTA, 0.035% SDS, pH 8.0). Enzyme reactions were initiated by the addition
of proteasome substrates. Substrates and concentrations were used as following: Suc-

LLVY-AMC (β5/5i, 100 µM), Ac-WLA-AMC (β5, 20 µM), Ac-nLPnLD-AMC (β1,100 µM),

Ac-RLR-AMC (β2/2i, 20 µM), Ac-ANW-AMC (β5i, 100 µM), and Ac-PAL-AMC (β1i

activity, 100 µM). Fluorescence signals were measured over 1 hour at one reading per

one minute using a SpectraMax M5 microplate reader at the excitation and emission
wavelengths of 360 and 460 nm, respectively.
3.2.5 Interferon-γ treatment
H727 and H23 cells were treated with 150 U⋅ml-1 of IFN-γ or vehicle for 24 h. At the
end of IFN-γ treatment, the cells were washed with PBS three times and then cultured

for an additional 24 hours. Afterwards the cells were sub-cultured into a 96-well plate,
and cell viability assays was performed using CellTiter 96 AQueous One Solution Cell
Proliferation assay (Promega, Madison, WI) as described above. The remaining cells
were then used for immunoblotting analysis and proteasome activity assays.
3.2.6 Knockdown of proteasome catalytic subunits
Cells were transfected with ON-TARGET Plus Smart Pool siRNAs (Dharmacon,
Lafayette, CO) using Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad,
CA), according to the manufacturer’s instructions. H727 cells were plated in a 6-well
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plate at a density of 5x105 cells per well and allowed at least 24 h to attach. Cells were
then transfected with 100 nmole of siRNAs and Lipofectamine 2000. At 4 h posttransfection, serum-free Opti-MEM medium (Invitrogen, Carlsbad, CA) was replaced
with complete medium and the cells were incubated for 48 h. The following siRNA

pools were used: PSMB5 (L-004522-00-0020), PSMB7 (L-006021-00-0020), PSMB8

(L-006022-00-0020), PSMB9 (L-006023-00-0005), and PSMB10 (L-006019-000020). For the negative control, human non-targeting scrambled siRNA (D-00181010) was used.

3.2.7 Preparation of primary MM samples
Cryopreserved MM primary cells isolated from the bone marrow or peripheral blood

of patients with no reported history of PI treatment were purchased from Conversant
Biologics (Huntsville, AL) and AllCells (Alameda, CA). CD138-positive cells were

isolated from patient samples immediately after thawing using human CD138

microbeads (Miltenyi Biotec), whole blood column kit (Miltenyi Biotec), MidiMACS
magnetic separator (Miltenyi Biotec), and 30 µm MACS SmartStrainers (Miltenyi

Biotec). Purified cells were plated on white 96-well cell culture plates at 40,000 cells

per well in RPMI 1640 media supplemented with 10% FBS. Cells were treated with
proteasome inhibitors for 48 hours before viability assessment via CellTiter-Glo
Luminescent Cell Viability Assay (Bio-Rad).
3.2.8 Statistics analysis
Results are expressed as means ± S.D. Statistical significance of the observed
differences was determined using Student’s t-test (with the Holm-Sidak method when

appropriate). All statistical analyses were carried out using GraphPad Prism 7.04
(GraphPad Software).

50

3.3 Results

3.3.1 H727 cells are intrinsically resistant to Cfz
To identify Cfz-resistant cell lines, we first measured the cytotoxic effects of

Cfz in 21 cancer cell lines derived from various types of cancer. These cell lines

displayed an array of Cfz sensitivities (IC50 values ranged from 9 to 610.2 nM). We
were especially intrigued by the marked lack of response to Cfz in the H727 human

non-small cell lung cancer (NSCLC) cell line; the Cfz I IC50 value for this cell line (610.2

nM) was approximately 33-fold higher than that for the Cfz-sensitive NSCLC cell line

H23 (18.3 nM) (Figure 3.1A). Even in the presence of 250 nM of Cfz which usually
induces >95% loss of viability in most of other cancer cell lines including H23 cells,

H727 cells survived and grew normally (Figure 3.1B). Thus, we selected the H727 cell
line as our cell line model of intrinsic resistance to Cfz in which to test our hypothesis.
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H23
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H727
Carfilzomib
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Figure 3.1 Sensitivity of H23 and H727 cells to Cfz
A. Cell viability (IC50 values) for a panel of established cancer cell lines as measured
by MTS assay following incubation with carfilzomib (Cfz) for 72 h. H727 cells are most

resistant to Cfz among 21 tested cell lines. B. Representative images of H23 and H727
cells growing in the presence of Cfz (100 or 250 nM, respectively) assessed via light
microscopy for 3 days.
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3.3.2 Previously reported mechanisms do not explain de novo resistance of H727 cells
While the mechanisms of intrinsic resistance to Cfz has not been reported to

date, several studies have shown that P-gp can contribute to acquired resistance to

Cfz observed in cancer cell line models and clinical samples from patients with prior
Cfz therapy [132-135]. To test whether P-gp plays a role in the de novo Cfz resistance

of H727 cells, we performed immunoblotting analysis but found no detectable P-gp

expression (Figure 3.2A). Furthermore, treatment of H727 cells with reversin 121, a

dipeptide P-gp inhibitor, did not significantly impact the IC50 value of Cfz (Figure

3.2B), confirming a P-gp-independent mechanism of resistance. Next, we examined

the possibility that Cfz may undergo rapid metabolic inactivation in H727 cells. We

treated H727 and H23 (Cfz-sensitive) cells with 500 nM Cfz and collected culture

media to measure the levels of remaining Cfz at 6 or 24 h post-treatment. The level of
remaining drug was overall comparable between H727 and H23 cells although a

slight difference was noted at 24 h (Figure 3.2C). Direct sequencing analyses also

indicated that the PSMB5 (encoding β5) and PSMB8 (encoding β5i) genes in H727
cells harbor no mutations (Figure 3.3A-D). We attempted to compare the intracellular

drug levels by quantifying the remaining drug levels in lysates of H727 and H23 cells,
but the levels were below the lower limit of quantitation (< 5 nM) of our current
analytical assay. Although it was not feasible to assess the intracellular drug levels,
H727 cells contained Cfz in the culture media at the level comparable to or slightly

higher than H23 cells. Assuming that Cfz primarily enters cells via passive diffusion

(no report yet supporting the presence of uptake transporters for Cfz as far as we

know), it appears unlikely that H727 cells have intracellular Cfz levels much lower
than H23 cells. Taken together, de novo resistance of H727 cells was not explained by
previously reported mechanisms such as P-gp upregulation, genetic mutations in
proteasome catalytic subunits, or enhanced metabolic inactivation of Cfz.
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Figure 3.2 Independency of H727 cells in previously reported mechanisms
A. Immunoblotting results showing no detectable expression of P-glycoprotein (P-gp)
in H727 cells. DLD-1 cells with acquired Cfz resistance via P-gp upregulation (DLD-

1/CfzR) were used as a positive control. B. The co-treatment of reversin-121 (7.5 µM,
P-gp inhibitor) did not affect the sensitivity of H727 cells to Cfz. The IC50 values did
not show statistically significant difference between in the presence and absence of
reversin-121 (Student’s t-test). C. The levels of remaining Cfz in culture media were

comparable between H727 and H23 cells (no statistically significant differences, ttests the Holm-Sidak method to correct for multiple comparisons with α = 0.05) (This

experiment was performed by Ji Eun Park from Wooin Lee’s group in the College of

Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National
University, Korea)
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A

Figure 3.3† Sequencing analysis of the PSMB5 and PSMB8 genes in H727 cells
A.

Alignment of truncated H727 PSMB5 forward sequencing read to PSMB5

NM_002797.4. B. Alignment of truncated H727 PSMB5 reverse sequencing read to

PSMB5 NM_002797.4. C. Alignment of H727 PSMB8E2 forward sequencing read to

truncated PSMB8E2 NM_148919.3 ORF. D. Alignment of H727 PSMB8E2 reverse

sequencing read reverse-compliment to truncated PSMB8E2 NM_148919.3 ORF.
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B

Figure 3.3† (continued)
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C

Figure 3.3† (continued)
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D

Figure 3.3† (continued)

† Sequencing analysis data of the PSMB5 and PSMB8 genes in H727 cells were

acquired by Zachary Miller.
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3.3.3 The proteasome remains essential for the survival of H727 cells
It is possible that cancer cells might have adaptations to endure reduced levels

of 20S proteasome function and the rely on the non-proteasomal protein degradation

pathways to reduce proteasome load. In order to verify whether the UPS is important
for the survival and proliferation of Cfz-resistant H727 cells, as it is in Cfz-sensitive

cell lines such as H23, we first transfected cells with siRNAs targeting the proteasome

α7 subunit in H727 cells, thereby blocking the assembly of active 20S proteasomes.
[270, 271]. As seen in Figure 3.4A, effective silencing of α7 resulted in almost complete

cell death after 3 days post-transfection for both in H727 and H23 cells, indicating
that active proteasomes remain indispensable for the survival of Cfz-resistant H727

cells. These results suggested that H727 cells may still respond to proteasome

inhibitors other than Cfz. In order to examine this, we treated H727 cells with
alternative PIs, particularly ones with differing pharmacophores or structures, such

as Btz (a peptide boronic acid) and MG-132 (a peptide aldehyde). These PIs were
indeed highly effective in killing H727 cells and their IC50 values were comparable

between H727 and H23 cells (Figure 3.4B). We also used two inhibitors targeting
various upstream components of the UPS, PYR-41, an inhibitor of ubiquitin E1 ligase

and several DUBs, and P5091, a specific USP7/USP47 inhibitor [245]. Both PYR-41
and P5091 were cytotoxic in H727 and H23 cells with comparable potencies (Figure

3.4B). These results further support that H727 cells remain dependent on the
ubiquitin-proteasome system, despite their de novo resistance to Cfz.
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Figure 3.4 Cytotoxic effect of targeting the UPS in H727 cells
A. Knockdown of proteasome α7 subunit in H727 cells effectively induced cell death
to a similar extent as observed in H23 cells (images taken 48 h post-transfection).

Immunoblotting analysis was performed to verify the efficient knockdown of α7 in
H727 cells. B. Comparison of the sensitivity (IC50 values) of H727 and H23 cells to

carfilzomib, bortezomib, MG 132, PYR-41 (an E1 inhibitor) and P5091 (an

USP7/USP47 inhibitor). Data are shown as mean ± SD derived from a non-linear
regression based on n=3-4 replicates per compound per concentration.
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3.3.4

H727 cells have a distinct composition of proteasome catalytic subunits

To account for the sensitivity of H727 cells to other PIs, we hypothesized

whether the subunit composition at the 20S proteasome level may contribute to de

novo resistance of H727 cells to Cfz. To test this hypothesis, we compared the
proteasome catalytic subunit expression and activity profiles of H727 and H23 cells

via immunoblotting analysis and kinetics assays using fluorogenic substrates for
individual subunits (β1, β5, β1i, β5i). In the case of the β2 and β2i subunits, their

combined trypsin-like activity was assessed due to the lack of a specific fluorogenic

substrate that can distinguish the two subunits. As shown in Figure 3.5A., the

expression pattern of proteasome catalytic subunits in H727 cells differed from that

in Cfz-sensitive H23, panc-1, and RPMI 8226 cells. H727 cells expressed high levels of
β1, β2, and β5i, while β1i expression was undetectable. The expression profile of

catalytic subunits in H727 cells was not consistent with those typically expected for
the two main 20S proteasome subtypes, namely a set of β1-β2-β5 for cP or an

immuno-subunit set of β1i-β2i-β5i for iP. Substantial differences were also noted
when the activity profiles of proteasome catalytic subunits were compared between
these two cell lines using subunit-selective fluorogenic substrates (Figure 3.5B).

Interestingly, the activity profiles of individual catalytic subunits showed
discrepancies with the protein levels of the respective catalytic subunits. We suspect

that the observed differences may reflect the complex relationship between

proteasome structure and function (e.g. contributions of post-translational
modifications, regulatory particles, or non-standard composition of proteasome
catalytic subunits to the hydrolysis rates of fluorogenic substrates).

We next examined whether individual subunits of proteasomes in H727 cells

may display different proteasome inhibition profiles than those of H23 cells. We

treated H727 and H23 cells with 20 nM of Cfz for 4 h and measured the remaining

activities of individual catalytic subunits relative to vehicle-treated control cells. As
shown in Figure 3.5C (left panel), more than 80% of β5, β5i and β1i activities were

blocked by Cfz for both H727 and H23 cells. On the contrary, over 50% of β1 activity
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persisted in H727 cells, but not in H23 cells (Figure 3.5C, left panel). It remains
unclear whether the remaining β1 activity contributes to de novo resistance of H727

cells to Cfz. On the other hand, Btz treatment resulted in over 80% inhibition across
all catalytic subunits in both H727 and H23 cell lines, which may explain the high

sensitivity of both cell lines to Btz (Figure 3.5C, right panel). These results support

that the 20S proteasomes present in H727 cells may be functionally different from
those in Cfz-sensitive H23 cells.
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Figure 3.5 Distinct composition of proteasome catalytic subunits in H727 cells
A. Immunoblots showing the differential expression of cP and iP catalytic subunits in

H727 and H23 cells as well as Cfz-sensitive panc-1 and RPMI 8226 cells. B. Differential
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proteasome activity profiles in H727 and H23 cell lines. Purified human 20S cP and
iP were used as controls for individual subunits: 20S cP for β5 and β1 and 20S iP for

β5i and β1i. The numbers represent hydrolysis rates of respective substrates
(RFU/min, mean values derived from three technical replicates) C. Remaining
catalytic activities of individual proteasome subunits in H727 and H23 cells 4 h after
treatment with 20 nM of carfilzomib (left panel) or 20 nM bortezomib (right panel).
Data are presented as mean ± SD derived from three technical replicates.
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3.3.5 A distinct composition of proteasome catalytic subunits in H727 cells
Based on the differential expression pattern of proteasome catalytic subunits

in H727 as compared to H23, we hypothesized that the composition of proteasome

catalytic subunits may impact the sensitivity of H727 cells to Cfz. To test this
hypothesis, we altered catalytic subunit composition in H727 using interferon-γ (IFN-

γ) treatment. IFN-γ’s ability to upregulate immuno-subunits (β1i, β2i, and β5i) and to

induce IP formation has been well-documented [37, 38]. As shown in Figure 3.6A,
incubation of H727 cells with IFN-γ (150 U⋅ml-1) 24 h prior to Cfz treatment resulted

in upregulation of immune-subunit expression and corresponding increases in their
activity. IFN-γ pre-treatment caused a significant decrease in Cfz IC50 values from

621.1 to 189.5 nM in H727 cells. When H23 cells were pre-treated with IFN-γ, the Cfz
IC50 values changed in the opposite direction (IC50 values increased from 18.6 to 44.1
nM, Figure 3.6B). With IFN-γ pre-treatment, the fold differences in IC50 values

between the two cell lines were reduced from 33-fold to 4.2-fold. Consistently, IFN-γ

pre-treatment also had effect on viability of RPMI 8226 cells with acquired Cfz
resistance. Human RPMI 8226 multiple myeloma cells with acquired resistance to Cfz
were established by adapting them in the presence of escalating concentrations of Cfz

up to 80 nM over 6 months. RPMI 8226 Cfz-resistant cells were cultured in 80 nM of
Cfz and then grown in the absence of Cfz for two weeks prior to the use. We have
observed the P-glycoprotein was overexpressed in RPMI 8226 Cfz-resistant cells

(Data shown in chapter 4). Regardless of P-glycoprotein overexpression, IFN-γ (150
U⋅ml-1) pretreatment could mediate the cellular response to Cfz (from 239.2 nM to
135.1 nM) in this cell line.
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Figure 3.6 Effect of IFN-γ pretreatment on H727 and H23 cells
A. IFN-γ (150 U⋅ml-1) pretreatment for 24 h led to increased expression (top left

panel) and activity (top right panel) of proteasome immuno-subunits. and sensitized
H727 cells to Cfz (bottom) B. IFN-γ (150 U⋅ml-1) pretreatment for 24 h desensitized

H23 cells towards Cfz. The IC50 values displayed a statistically significant difference
between IFN-γ-pretreated cells and vehicle control in both of H727 and H23 cells. (P

value < 0.01, n=3, Student’s t-test comparing the log transformed IC50 values obtained

from three independent runs).
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3.3.6 Alteration of proteasome catalytic subunit composition affects H727 Cfz
sensitivity

In order to further investigate a causal relationship between the composition

of proteasome catalytic subunits and Cfz sensitivity, we sought to alter the
composition of proteasome catalytic subunits in H727 cells in a more selective

manner using an siRNA pool targeting the abundantly expressed β5 subunit. We

expected that β5i will substitute for β5 during proteasome assembly, forming 20S
complexes with altered catalytic subunit composition. When β5 was knocked down

(verified via immunoblotting and activity assays, Figure 3.7A & B), H727 cells grew

normally with modest upregulation of β5i. Despite their normal growth, H727 cells

were significantly sensitized to Cfz by β5 knockdown, shifting the IC50 value from 622

to 99.9 nM (Figure 3.7C). In contrast, the IC50 for Btz was only modestly affected,

decreasing from 26 to 12 nM (Figure 3.7D). Knockdown of other catalytic subunits
such as β5i and β2 resulted in minimal changes in the IC50 values for Cfz. A similar

pattern was observed in H23 cells where knockdown of β5i and β2 had little effect on
Cfz sensitivity but β5 knockdown triggered a five-fold reduction in Cfz IC50 from 26.7
to 5.0 nM (Figure 3.7C).
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Figure 3.7 The effect of catalytic subunit knockdown on H727 cells
A. Immunoblots of proteasome catalytic subunits in H727 cells transfected with
siRNA targeting β5, β2 or β5i. B. The catalytic activity of β5 subunit was decreased in

H727 cells transfected with siRNA targeting β5 compared with H727 cells transfected

with scrambled siRNA. C. Effects of siRNA knockdown of β5, β5i, or β2 on Cfz
sensitivity (IC50 values) in H23 and H727 cells. Data are shown as mean ± SD derived
from a non-linear regression based on n=3 replicates per compound per

concentration. D. 72 h cell viability for Bortezomib 48 h after siRNA knockdown β5 in

H727 cells
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3.3.7 The proteasome activity profiles of primary MM cells is highly variable
In order to assess whether the observed variability in proteasome activity

profiles in PI-naı̈ve cell line models reflects the Cfz sensitivity of clinical MM samples,
we examined the proteasome activity profiles and degree of Cfz sensitivity using 6
MM samples from patients who have received no prior PI therapy. Similar to the

results obtained using cell line models, the clinical samples also showed considerable

variability in catalytic subunit activity profiles and Cfz sensitivity (Figure 3.8 A & B).

Due to the limited sample quantities, we were not able to perform any further
investigations on these samples. Based on these initial assessments, we cautiously

speculate that differential Cfz sensitivity in these patient samples may be influenced
by variability in proteasome catalytic subunit composition, perhaps partially

accounting for the varied responses to Cfz observed in clinical trial results [260, 263,

264].
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B

Figure 3.8 Activity profile and viability for Cfz in primary MM samples
A. Heat map showing proteasome catalytic subunit activity profiles of 6 PI-naïve
patient MM samples purchased from Conversant Biologics and AllCells. The numbers

represent hydrolysis rates of respective substrates (RFU/min, mean values derived
from three technical replicates) and were converted to color format and clustered by

using the program “R” (http://www.R-project.org) B. Carfilzomib (Cfz) cell viability

of the same 6 patient MM cells was measured via CellTiter-Glo Luminescent Cell

Viability Assay.
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3.4 Discussion

Cfz has contributed to a substantial advancement in multiple myeloma

treatment by improving patient survival and quality of life. A considerable portion of
patients however display intrinsic resistance to Cfz. A significant portions of MM

patients previously treated with Btz-containing regimens do not respond to Cfz and

even those who initially respond to Cfz almost ultimately develop resistance in the

course of their treatment [260, 266]. In order to design new and effective therapeutic
strategies to overcome resistance, it is important to better understand the

mechanisms of Cfz resistance. To date, investigations of Cfz resistance have largely

focused on acquired resistance due to the relative ease of generating Cfz-adapted
cancer cell lines and the availability of clinical samples derived from patients who

have developed resistance after prolonged Cfz therapy. On the other hand,
mechanistic investigations of de novo Cfz resistance have been scarce, due to the lack

of appropriate cell line models and patient samples.

In the current study, we report that H727 cells are intrinsically resistant to Cfz,

potentially serving as a useful model for mechanistic investigations of de novo Cfz
resistance. Given that H727 cells were sensitive to inhibitors of non-proteasomal

targets in the UPS and PIs other than Cfz, we surmise that H727 cells harbor

functionally active proteasomes and that complete or near-complete inhibition of
proteasome catalytic activity is incompatible with survival in these cells. Based on our
current results, a shift towards non-UPS protein degradation pathways appears

unlikely since H727 cells remain highly sensitive to the inhibition of UPS components
including the proteasome itself.

Despite their similar degrees of dependence on the proteasome or UPS for

survival and growth, H727 and H23 cells respond differently to Cfz, to a degree of 33fold difference in IC50 values. This may be in part due to cell line-dependent cell

growth rates or genetic/molecular differences. However, the high sensitivity of H727
cells to other PIs suggests that Cfz resistance in H727 cells may be mediated at the

20S proteasome level. It has been reported that proteasome inhibitor resistance is
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often associated with increased levels of proteasome subunit catalytic activity,

especially in models of acquired bortezomib resistance [117, 272]. However, H727

cells displayed substantially low activities of individual catalytic subunits as

compared to H23 cells. At present, it is unclear whether the low proteasome activities
in H727 cells are involved in conferring Cfz resistance. Previously it was reported that
20S proteasomes harboring a mixed assortment of cP and iP catalytic subunits exist

in cancer cells and that their PI sensitivity differs from those of standard cP or iP5.
Our results also indicated not only differing expression levels of proteasome catalytic
subunits between H727 and H23 cells, but also differing levels of subunit catalytic
activity. These findings are consistent with the presence of non-standard 20S
proteasome subtypes (other than cP and iP). Determination of the 20S proteasome
subtypes present in H727 cancer cells may shed further light on the underlying

mechanisms of de novo Cfz resistance in H727 cells. Determination of the subunit
composition of intact 20S proteasomes in cells is challenging and several groups

including ours are currently trying to develop bi-functional or fluorescent probes to
facilitate these efforts [273, 274].
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CHAPTER 4. DEVELOPMENT OF NOVEL EPOXYKETONE-BASED PROTEASOME
INHIBITORS AS A STRATEGY TO OVERCOME CANCER RESISTANCE TO
CARFILZOMIB AND BORTEZOMIB
Some of the work in this chapter has been accepted in Journal of Medicinal
Chemistry 2019 [334].
4.1 Introduction

In 2003, the FDA approval of first-in-class Proteasome inhibitor (PI)

bortezomib (Velcade®, Btz) for treating patients with multiple myeloma (MM)

validated the proteasome as an anticancer target. A decade later, the FDA approved
a second-in-class PI—carfilzomib (Kyprolis®, Cfz) and ixazomib (Ninlaro®, Ixz)—for

treating patients with relapsed MM, firmly establishing the proteasome as an exciting
target in treating cancer. Although the use of PIs in MM patients has successfully

improved clinical outcomes, a subset of PI-naïve patients failed to respond to these

inhibitors, and almost all patients who do respond eventually acquire PI resistance
[105, 261, 263]. Recently, three non-PI drugs, daratumumab (a monoclonal antibody

(mAb) targeting CD38), elotuzumab (mAb targeting SLAMF7) and panobinostat
(HDAC inhibitor) were approved for treatment of relapsed MM. While these non-PI

drugs provide additional options for MM patients relapsed on current PI-based

therapies, a portion of patients still do not respond to these therapies. The results

from recent clinical trials show that the response for these non-PI drugs is rather

transient with the median duration of ~7-20 months before relapsing [275-277].

Therefore, it is now critically important to develop new therapeutic strategies that

can overcome the limitations of the FDA-approved PIs and deliver the therapeutic
benefits of PIs to cancer patients who have exhausted current treatment options.
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The ubiquitin proteasome system (UPS) remains essential for cancer cells

regardless of resistance to existing PI drugs. The UPS upstream components of the
proteasome such as ubiquitin E3 ligases and deubiquitinases are being explored as
potential anti-cancer therapeutic targets [245, 246, 278], but not be successful yet.
Alternatively, it remains to be seen whether the proteasome itself can be

subsequently re-targeted to achieve further therapeutic gains for MM patients
relapsed on existing PI drugs.

Most of PIs have been developed through medicinal chemistry approach,

optimizing amino acid side chains (P1, P2, P3) which interact with the substrate

binding pockets (S1, S2, S3, etc.) of proteasome catalytic subunits. This binding
configuration is further stabilized by anti-parallel β-sheet conferring hydrogen

bonding interactions between the inhibitor’s peptide backbone and conserved
residues such as Thr21, Gly47, and Ala49 of proteasome catalytic subunits [279-281].
When combined with a C-terminal warhead which targets the catalytic Thr1 residue,
this strategy typically yields potent inhibitors including the three FDA-approved PIs:
Btz, Ixz (peptide boronic acids) and Cfz (a peptide epoxyketone). However, this

strategy might have unintentionally contributed to an increased cross-resistance

among them. A potential strategy to overcome PI cross-resistance is to identify and
exploit a structural niche not utilized by existing PIs. In that regard, previously
unexplored are P1′ binding sites which lie on the C-terminal side of the proteasome
catalytic subunit’s cleavage site.

Here, we have developed peptide epoxyketones having a P1′-targeting moiety.

The anticancer efficacy of these compounds was superior to their non-P1′-targeting

parent compounds when evaluated against models of intrinsic and acquired Cfz
resistance. The identified lead compound, Cfz-OH, an analog of Cfz containing a

hydroxyl group at the P1′ position, displayed potent proteasome inhibitory activity
and cytotoxicity in both Cfz-sensitive and Cfz-resistant cancer cell lines.
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4.2 Material and Methods

4.2.1 Chemistry

Peptide epoxyketones having a P1′-targeting moiety were synthesized by Dr. Deepak

Bhattarai.

4.2.2 Enzyme kinetic assay

Purified human 20S immunoproteasome (Boston Biochem) or RPMI 8226 cell lysates
were diluted in 20S proteasome assay buffer (20 mM Tris-HCl, 0.5 mM EDTA, 0.035%

SDS, pH 8.0) and incubated with various concentrations of each inhibitor for 1 h in a
96-well plate. The fluorogenic substrates Suc-Leu-Leu-Val-Tyr-AMC (Bachem) or AcPro-Ala-Leu-AMC (Boston Biochem) were used at the final substrate concentration of

100 μM to measure the remaining levels of chymotrypsin-like activity or LMP2-

specific catalytic activity, respectively. Fluorescence signals from the release of free

AMC (7-amino-4-methylcoumarin) were monitored every minute for 1 h via a
SpectraMax M5 microplate reader (Molecular Devices) using excitation and emission
wavelengths of 360 and 460 nm, respectively. The initial hydrolysis rates (slopes) for

individual wells were calculated via linear regression and normalized to the values

from vehicle-treated control wells. Non-linear regression analysis was performed
using GraphPad Prism 7 to calculate an IC50 value for each compound in inhibiting
proteasomal CT-L or LMP2 activity.
4.2.3 Cell culture

Human cancer cell lines H23, H727, and RPMI8226 were obtained from the ATCC

(American Type Culture Collection) and maintained in the ATCC recommended media,
RPMI1640 supplemented with 10% fetal bovine serum (Gibco, and Atlanta
Biologicals). RPMI8226 cells with acquired resistance to Cfz were established by

adapting them in the presence of stepwise increasing concentrations of Cfz up to 80
nM over a period of approximately 6 months. Cfz-resistant cells were maintained in
76

80 nM Cfz and then grown in the absence of Cfz for approximately one week prior to
the experiments.

4.2.4 Isolation of primary MM samples

Bone marrow (BM) aspirates were obtained from patients after approval by the UC

Cancer Institute Institutional Review Board followed by positive selection with
CD138 microbeads developed for the isolation of plasma cells. Immunophenotyping

by flow cytometry was performed to confirm the purity and quantity of selected
CD138+ plasma cells.
4.2.5 Cell Viability

4.2.5.1 Established cancer cell lines

H23 cells or H727 cells were plated at 5,000 or 10,000 cells per well, respectively.
RPMI8226 cells and Cfz-resistant RPMI8226 sublines growing in suspension were

plated at 10,000 cells per well. Twenty-four hours after plating, media containing the

test compounds were added to each well to deliver the intended final concentration.
After 72 h, cell viability was determined using the assay protocol recommended by

the manufacturer (CellTiter 96 Aqueous One Solution Cell Proliferation assay,

Promega). The resulting signals were measured using a SpectraMax M5 microplate

spectrophotometer (Molecular Devices). Non-linear regression analysis was
performed using GraphPad Prism 7 to calculate an IC50 value for each compound to

incur cell death.

4.2.5.2 Primary MM cells

Purified primary MM cells were plated on 96-well plates at a density of 20,000 cells

per well in IMDM media (Gibco) supplemented with 10% FBS. After cells were treated
with test compounds for 48 h, the percentage of viable cells was determined using the

CellTiter Glo Luminescent Cell Viability Assay (Promega) and a Veritas microplate
luminometer (Promega).
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4.2.6 Immunoblotting

Cell lysates were prepared using ice-cold RIPA lysis buffer (50 mM Tris–Cl, 150 mM

NaCl, 1% NP-40, 1% Triton X-100) supplemented with 1% protease inhibitor cocktail

(Sigma–Aldrich). After centrifugation at 14,000g at 4 °C for 20 min, the resulting
supernatant was collected and subject to the total protein assay using Protein Assay

Dye Reagent Concentrate (Bio-Rad). Proteins were resolved by 7.5% SDS-PAGE, and
transferred onto PVDF membranes (Bio-Rad) via semi-dry transfer. After blocking in

5% nonfat dry milk, membranes were incubated with primary antibodies (anti-P-gp

(Abcam) or anti-β-actin (Enzo)) at 4 °C overnight. Membranes were washed and
incubated with appropriate peroxidase-conjugated secondary antibodies for 1 h at

room temperature. Proteins were visualized on Kodak BioMax XAR Films (Sigma–
Aldrich) using ECL.

4.2.7 In vitro metabolic stability

To assess whether Cfz-OH has indeed an improved metabolic stability over Cfz, we

compared the rate by which Cfz-OH or Cfz disappears in the presence of rat liver
homogenates, as previously reported [282]. Briefly, the liver was obtained from male
Sprague-Dawley rats (8 week-old, Nara Biotech Co. Ltd., Seoul, Korea) using the

protocol approved by the Seoul National University Institutional Animal Care and Use
Committee (approval No. SNU-160512-5-1). The harvested liver was washed with
phosphate-buffered saline (PBS, pH 7.4) and homogenized using 5-fold excess volume

of PBS per g tissue. After pre-incubation at 37 °C, an aliquot of liver homogenates was
spiked with the stock solution of Cfz or Cfz-OH to achieve the final concentration of 1
M (total volume of 400 µl, n=3). At the pre-designated time (0, 5, 10, and 20 min), an
aliquot (40 µl) was collected and mixed with 4-fold excess volume of ice-cold

acetonitrile containing chlorpropamide (an internal standard, IS, 0.5 µM). After
vortexing and centrifugation, the drug levels in the resulting supernatant were
analyzed via HPLC interfaced with mass spectrometry (LC-MS/MS).
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Cfz-OH was quantified using the slightly modified analytical conditions via LC-MS/MS

(1260 infinity HPLC system interfaced with 6430 Triple Quad LC-MS system, Agilent

Technologies, Palo Alto, CA) in a positive ion mode. The chromatic separation was
performed using a Poroshell 120 EC-C18 column (4.6 x 50 mm, 2.7 µm, Agilent

Technologies, Palo Alto, CA) and an isocratic mobile phase composed of acetonitrile

and water (75:25, v/v) at a flow rate of 0.3 mL/min. The retention time of Cfz-OH was

1.7 min and the gas temperature was set at 300 °C. The source-dependent parameters,
the fragment voltage, collision energy and cell accelerator voltage were set as follows:

170 V, 75 V, and 1 V for Cfz-OH and 90 V, 30 V and 7 V for chlorpropamide (IS).

Quantification was performed in the selected reaction monitoring (SRM) mode using
the following transitions: m/z 736.2 > 99.9 for Cfz-OH and m/z 276.9 > 110.8 for

chlorpropamide (IS). The calibration samples were prepared in the range of 1 to 200

nM and the signals showed linearity with the r2 value greater than 0.98. The data

were processed using the MassHunter Workstation Software Quantitative Analysis
(vB.05.00; Agilent Technologies).
4.3 Results

4.3.1 Initial screening for proteasome inhibitors that overcome intrinsic Cfz resistance

As described in chapter 3, H727 human lung adenocarcinoma cell line is

intrinsically resistant to Cfz (IC50 of 611 nM) compared to a panel of cancer cell lines

(IC50’s in the low nM range). Thus, we selected the H727 cell line as our cell line model
of intrinsic resistance to Cfz in which to identify PIs that can overcome de novo

resistance to Cfz. As a control, we used another lung cancer cell line model of H23
cells, which are highly sensitive to Cfz (IC50 of 18 nM). We treated theses Cfz-sensitive

H23 and Cfz-resistant cancer H727 cell lines with PIs that have distinct chemical
structures and pharmacophores—The peptide epoxyketone inhibitor carfilzomib, the

peptide boronate inhibitor bortezomib, the peptide aldehyde inhibitor MG-132, the

in-house-generated peptide epoxyketone inhibitors UK-101 and UK-102, and the β79

lactone inhibitor lactacystin (Figure 4.1)—for 72 hours. We then measured the effects
of each inhibitor on cell viability. UK101 and UK102 were previously developed in

our laboratory [283]. Interestingly, compared to Cfz, UK-101 and UK-102, displayed

relatively smaller differences in their IC50 values between Cfz-sensitive and Cfz-

resistant cancer cells (Table 4.1). In other words, UK101 and UK102 displayed a

comparable cytotoxicity in H727 and H23 cells. In addition, Cfz-resistant cancers may
be minimally cross-resistant to UK-101 and UK-102. On the other hand, a β-lactone
inhibitor lactacystin was not as effective in H727 cells as in H23 cells. These results

suggest that targeting the proteasome using alternative PIs still can be a viable

therapeutic option even in the presence of cancer resistance to Cfz and Identifying
alternative PIs that remain effective in Cfz-resistant cancer cells.
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Figure 4.1 Structures of structurally distinct-proteasome inhibitors
Structures of the peptide epoxyketone inhibitor carfilzomib, the peptide boronate

inhibitor bortezomib, the peptide aldehyde inhibitor MG-132, the β-lactone inhibitor

lactacystin, and the in-house-generated peptide epoxyketone inhibitors UK-101 and
UK-102 are shown
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Table 4.1 Cytotoxicity of proteasome inhibitors in H727 and H23 cells

IC50 (µM)

Carfilzomib
Bortezomib
MG-132
Lactacystin
UK101
UK102

Fold difference

H23

H727

0.018 ± 0.004

0.611 ± 0.047

33.3

0.48 ± 0.01

0.98 ± 0.03

2

0.010 ± 0.001

0.025 ± 0.006

5.23 ± 0.22
3.37 ± 0.19
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2.5

> 100

> 19

4.49 ± 0.26

1.3

5.21 ± 0.11

3.40 ± 0.18

(H727/H23)

1.5

4.3.2 The PIs with P1’ (UK101 & UK102) exert the anticancer efficacies in acquired Cfz
resistant cancer cells

Since acquired cfz resistance is a major clinical challenge facing Cfz-based

therapies, we wondered whether these P1′-targeting epoxyketones, UK101 and

UK102 are also effective in acquired Cfz resistance cells. To test this, we established
a Cfz-resistant subline of human MM RPMI8226 and U266 (RPMI 8226/CfzR and
U266/CfzR) by culturing them in the continuous presence of gradually increasing

concentrations of Cfz over 6 months. As shown in Figure 4.2 A&B, results from MTS

cell viability assays revealed that, in comparison with those of their respective
parental cell lines, the Cfz IC50 values of RPMI 8226/CfzR and U266/CfzR cells were
36-fold and 9-fold higher, respectively.

As described previously, several studies have shown that the efflux

transporter P-gp can contribute to acquired resistance to Cfz observed in cancer cell
line models and clinical samples from patients with prior Cfz therapy [132-135]. To
test whether P-gp plays a role in these RPMI 8226/ CfzR and U266/ CfzR cell line

models, we performed immunoblotting analysis to detect P-gp expression (Figure

4.3A). While there is no delectable level of P-gp expression in PRMI 8226 or U266

parental cells, the highly elevated expression of P-gp in both RPMI 8226/CfzR and

U266/CfzR cells. Furthermore, treatment of RPMI 8226/CfzR cells with 7.5 µM of

reversin 121, a dipeptide P-gp inhibitor, did not significantly impact the IC50 value of

Cfz (Figure 4.3B), confirming the predominant contribution of P-gp in the current

model of acquire Cfz resistance. Using these acquired Cfz resistant cell line modesl,
we examined the effectiveness of P1′-targeting epoxyketones. As reported before,
both epoxyketone PIs Cfz and epoxomicin displayed a marked increase in IC50 values,

indicating there are P-gp substrate. On the other hand, compared to Cfz, UK-101 and

UK-102, displayed relatively smaller differences in their IC50 values between Cfzresistant cancer cells and their parental controls (Table 4.2).
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A

B

Figure 4.2 Establishment of MM cell lines with acquired resistance to Cfz
A. 72 h cell viability data for Cfz in RPMI 8226 parental and Cfz-resistant cells are

shown. B. 72 h cell viability data for Cfz in U266 parental and Cfz-resistant cells are
shown.
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A

B

Figure 4.3 P-gp overexpression in acquired Cfz resistant MM cells
A. Immunoblotting results showing elevated expression of P-glycoprotein (P-gp) in
RPMI 8227 and U266 cells with acquired Cfz resistance. B. The co-treatment of

reversin-121 (7.5 µM, P-gp inhibitor) restored the sensitivity of RPMI 8226/CfzR cells
to Cfz. Data shown are representative of biological triplicate experiments.

85

Table 4.2 Cytotoxicity of proteasome inhibitors in acquired Cfz resistant cells
IC50 (nM)

Carfilzomib
Epoxomicin
UK101

UK102

RPMI

RPMI

8266

8266/CfzR

7.4 ± 1.5

11.3 ± 5.9
2147 ±
803

1753 ±
113

U266

U266/CfzR

269.8 ± 55.6

8.9 ± 1.1

73.7 ± 10.4

3728 ± 105

1818 ± 891

7096 ± 844

9651± 902

1809 ± 109

1284 ± 114

540.9 ± 58.0

ND

ND

Data are reported as the mean ± SD. For epoxomicin and carfilzomib, the SD values

were obtained from three independent experiments. For UK101 and UK102, the SD
values were from non-linear regression analysis using three replicates.
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4.3.3 UK101 and UK102 exert the anticancer efficacy in acquired Btz resistantprimary MM samples

In order to further validate that UK-101 and UK-102 have anticancer efficacy

in Cfz-resistance, we examined whether UK101 and UK102 can be also effective in
primary MM samples derived from patients who do not respond to Btz. Since we were

unable to obtain MM samples from patients who are resistant to Cfz, we only obtained

primary cells from two different patient groups: patients who did not respond to Btz
therapy (Btz-resistant patients), and patients who were never treated with Btz or Cfz
(PI-naïve patients), but it was previously reported that patients with MM refractory

to or relapsed on Btz are often cross-resistant to Cfz [260]. Using the primary MM

samples from 14 different donors (6 from PI-naïve patients and 8 from patients
relapsed on Btz therapy), we treated these primary MM cells for 48 hours with Cfz,
UK-101, or UK-102 at its in vitro IC80 concentration derived from viability assay in cell

line models via CellTiter-Glo® Luminescent Cell Viability Assays. In this assay, we

found varying degrees of sensitivity to Btz or Cfz, but the MM samples from the
patients who relapsed on Btz tended to be less responsive to both Btz and Cfz than

those from patients from the PI-naïve group (Figure 4.4 A & B). Due to limited
quantities of primary MM samples from 6 patients (#1-#4, #9, and #10), we only
utilized 10 primary MM samples (4 Btz-resistant and 6 PI-naïve) to examine the

efficacy of UK101 or UK102. When 10 primary MM samples treated with UK101 or

UK102 for 48 h, the results showed UK-101 and UK-102 remained much more active
in primary MM cells derived from Btz-resistant patients and the PI-naïve patients in

a dose dependent manner (Figure 4.4 C & D). These results suggest that alternative

PIs such as UK-101 and UK-102 may have valuable clinical potential and warrant
further investigation. Furthermore, the lack of apparent cross-resistance between

Cfz/Btz and UK101/UK102 was encouraging although the current sample size was

small.
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A

B

C

D

Figure 4.4 Cytotoxic effects of bortezomib, carfilzomib, UK101, and UK102 on
primary MM samples
A. Viability for 50 nM of Btz in primary MM cells derived from Btz-resistant patients

and PI-naïve patients B. Viability for 50 nM of Cfz in primary MM cells derived from

Btz-resistant patients and PI-naïve patients C. Viability for 10 or 15 µM UK-101 in
primary MM cells derived from Btz-resistant patients and PI-naïve patients D.

Viability for 10 or 15 µM UK-102 in primary MM cells derived from Btz-resistant

patients and PI-naïve patients.
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4.3.4 Introduction of hydrophilic residues at the P1’ position of peptide epoxyketones
enhances the potency of the proteasome inhibition.

Since we observed that UK101 and UK102 had anti-cancer efficacy in primary

samples derived from Btz-resistant patients but displayed display much lower

potencies than Btz and Cfz with IC50 values, we first utilized a previously reported

docking model of UK101 bound to β1i and β5, known targets of UK101 to improve
the potency of UK101/UK102 and obtain structure-activity relationship (SAR)

information [84, 283]. As shown in Figure 4.5, the P1-P3 residues of UK101 were

predicted to occupy the S1-S3 pockets located deep inside of the active sites of the β1i

and β5 subunits. However, unlike Cfz bound to β5, docking followed by molecular

dynamics simulations indicated that UK101 occupies an additional binding pocket

(S1′) of the β5 as well as β1i subunits via its P1′ group (highlighted in purple circles,
Figure 4.5) which is not occupied by Cfz or Btz. Although the P1′ group (t-

butyldimethylsilyl, TBDMS) of UK101 is not predicted to participate in any specific
interactions upon binding to β1i, it fully occupies the S1′ pocket defined by the

surrounding polar amino acids (Ser21, Ser48, Ser95, His97). In the case of UK101
bound to β5, a steric clash between the TBDMS group and Tyr169 is noted. The

resulting change in conformation is predicted to abolish a potential hydrogen bond
between UK101 and Gly47, a plausible contributing factor towards UK101’s low

potency against the β5 subunit [284]. We hypothesized that the optimization at the
P1′ position could provide energetically-favorable interactions with the S1′ pocket of

β1i and also avoid steric clash with Tyr169 of β5, potentially improving potency

against both subunits. To test this, we replaced the bulky hydrophobic P1′ substituent

(TBDMS) of UK101 with a hydroxyl group (scheme in Figure 4.6) and assessed its
impact. This simple P1′ substitution increased in vitro 20S proteasome inhibitory
potency by ~4-10 fold (Table 4.3). Moreover, the P1′ hydroxyl group also

considerably improved the cytotoxic activity of UK101-OH (5) cancer cell lines,

including our models of both de novo and acquired Cfz resistance. Based on this result,
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we suspect that the P1’ residue of peptide epoxyketones may play an important role
in overcoming the resistance of cancer cells to Cfz.
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Figure 4.5 Predicted docking models of UK101 and Cfz bound to β5 or β1i
Predicted docking models of UK101 and carfilzomib (Cfz) bound to β5 or β1i. The
superposition of the β5 and β1i active sites are shown based on molecular dynamics

simulations. The location of UK101’s TBDMS group positioned within putative P1′

pockets is highlighted using a purple-colored circle. X-ray structures of β1 (PDB ID:
3UNF) and β5/X (PDB ID: 3UNE) from mammalian 20S proteasomes were used as

templates for modeling LMP2 and X. This experiment was performed by Dr. Chang-

Guo Zhan’s group in the College of Pharmacy, University of Kentucky.
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Figure 4.6 Synthetic scheme for UK101-OH (5)
These compounds including UK101-OH(5) were synthesized by Dr. Deepak Bhattarai.
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Table 4.3 Cytotoxicity of proteasome inhibitors in H727, H23, RPMI 8226/CfzR
cells
IC50 (µM)

Proteasome
inhibitors

CT-L

UK101

> 10

5
(UK101-OH)

1.7 ±
0.1

RPMI

LMP2

H23

H727

0.140 ±

3.37 ±

5.21 ±

2.14 ±

0.036 ±

0.58 ±

0.69 ±

0.31 ±

0.01

0.19

0.01

0.02

Data are reported as the mean ± SD.
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0.11
0.01

8266/CfzR

0.08
0.01

4.3.5 Development of Cfz analog with an improved potency in de novo and acquired
Cfz resistant models

In our efforts to further optimize UK101-OH, we deemed that the P1-P4 groups

of Cfz have already been thoroughly optimized for the S1-S4 pockets of β5 and β5i (as

well as β1i, to a lesser extent, based on the largely β1i/β5 superimposed model,
Figure 4.5). We thus decided to attach several different P1′ moieties to Cfz. Since we

have observed that Cfz analogs bearing a P1′-targeting group could overcome cross-

resistance to Cfz, we also expected that a Cfz analog containing a polar P1′ moiety
leading an improved inhibitory potency against both β5 and β1i compared to Cfz, due

to additional P1′:S1′ interactions. Based on this, we prepared Cfz analogs having a

series of P1′ moieties varying from bulky hydrophobic to small hydrophilic residues
(synthetic scheme in Figure 4.7). We subsequently measured their activity against

cell lysates to measure CT-L (β5/β5i) inhibition and against 20S purified

immunoproteasomes to measure β1i inhibition. As predicted by molecular dynamics,

Cfz-OH and Cfz-Sulfone having small polar moieties were most potent in vitro with

IC50 values similar to that of Cfz. When these two compounds were tested using Cfzresistant H727 cells, Cfz-Sulfone (12) was less potent than Cfz against H727. On the
other hand, Cfz-OH, a Cfz analog (9) with a hydroxyl group at the P1′ position,
demonstrated an improved potency by ~10-fold relative to Cfz. When tested against

RPMI8226 with acquired Cfz resistance, Cfz-OH (9) demonstrated an almost 3-fold

improvement in potency against Cfz-resistant RPMI8226 cells as compared to Cfz
(Figure 4.8).
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Figure 4.7 Synthetic scheme for Cfz-OH (9)
These compounds including Cfz-OH (9) were synthesized by Dr. Deepak Bhattarai.
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Figure 4.8 Effects of various substitutions at the P1′site of the compound on the
potency in Cfz resistant cells
The potency (IC50 values) for compounds with various substitutions at the P1′site

against proteasome chymotrypsin-like activity (RPMI8226 cell lysate), LMP2 activity

(purified human 20S immunoproteasome), and cell viability of H23, H727, and Cfzresistant RPMI8226 cells. Data reported as the mean ± SD (carfilzomib, n = 3
independent experiments) or from a single experiment (3 replicates, 7, 9, and 12).
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4.3.6 Cfz-OH has improved metabolic stability compared to Cfz
Due to the presence of peptidase and microsomal epoxide hydrolase (mEH) enzymes

throughout many of the body’s tissues, the peptide epoxyketone inhibitor carfilzomib
is metabolized extremely rapidly, likely contributing to poor activity against solid
tumors [285-287]. While cytochrome P450 is well known as a major enzyme to

metabolize most of drugs, metabolites formed via P450 enzymes were only detected
at very low levels. An in vitro study using rat tissue homogenates has confirmed that

carfilzomib metabolism is not restricted to the liver and that lung, kidney, and heart

tissues all possess the ability to rapidly degrade carfilzomib to its inactive metabolites.
In the case of mEH, the active site harbors two conserved Tyr residues which may
contribute to substrate specificity and orientation of substrates within the active site
[288, 289]. The prototypical substrates of mEH include planar hydrophobic
compounds such as various epoxides of polycyclic aromatic hydrocarbons and
steroids [290]. It is thus expected that the epoxide ring of Cfz occupies the active site
of mEH with a position suitable for hydrolysis to yield Cfz-diol (Figure 4.9). We

hypothesized that the addition of a hydroxyl group adjacent to the epoxide ring of Cfz,

Cfz-OH, may hinder the hydrolysis of the epoxide ring by inhibiting access to the
active site of mEH. To assess whether Cfz-OH has indeed an improved metabolic
stability over Cfz, we compared the rate by which Cfz-OH or Cfz disappears in the

presence of rat liver homogenates, as previously reported [282]. In the presence of
rat liver homogenates, Cfz-OH was metabolized much more slowly than Cfz. In this

case ~40% of Cfz-OH remained unmetabolized at 5 minutes as compared to just 7%

of carfilzomib (Figure 4.9). Based on these preliminary results we found Cfz-OH was

indeed more stable than Cfz.
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A

B

Figure 4.9 The metabolic stability of CFZ-OH
A. Schematic depicting the rapid metabolism of Cfz by microsomal epoxide hydrolase
(mEH) to the inactive diol. B. Quantification of the remaining levels of Cfz or 9

following the incubation with rat liver homogenate containing active mEH and
peptidase activities for 5, 10, and 20 minutes respectively. Data presented as mean ±
SD. This experiment was performed by Zi Soo Yoo from Wooin’s group in the College

of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National
University, Korea.
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4.4 Discussion

It is now well-understood that proteasome inhibitor resistance, either de novo

or acquired, is a major limitation associated with the clinical use of PI drugs in treating

cancers. In patients with refractory/relapsed MM, response rates for Btz and Cfz are
less than 50% and 25%, respectively. Although the response rates can increase to
~70-90% when combined with other drugs including lenalidomide, all patients
inevitably develop resistance to therapy and have a dismal prognosis once resistance

emerges. While several PI resistance mechanisms have been proposed so far, their

clinical relevance is yet to be validated. Currently, the lack of the mechanistic
understanding of PI resistance is a major obstacle in improving MM patient care.

Mounting evidence has demonstrated that the proteasome remains necessary

for cancer cells survival regardless of their resistance to PI drugs. The proteasome

plays important roles in various cellular functions and to date there appears no
pathway which can fully compensate for the loss of proteasome function. Several
reports supported that proteasome inhibition may offer therapeutic gains even in
patients with MM relapsed/refractory to currently used PIs in clinic.

In this study, we used two type of PI resistant cancer cell lines, de novo Cfz

resistant H727 cells or acquired Cfz resistant RPMI 8226/CfzR, U266/CfzR cells. We

identified an effective proteasome inhibitor compound against both de novo or

acquired Cfz resistant cell lines. We found that epoxyketones with P1′ substituents
can overcome both de novo and to a lesser degree, acquired Cfz resistance in cell line
models. It is well known peptide epoxyketones harbor greater selectivity in their

interactions with the proteasome catalytic subunit by forming an 1,4-oxazepane
adduct with the N-terminal catalytic threonine residue of the proteasome [75],

leading to the improved safety profiles of Cfz over other classes PIs including the
peptide boronate Btz. We believe that the compound with improved metabolic

stability and ability to overcome resistance mechanisms may offer valuable

knowledge for further drug development. Future studies will address the in vivo
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efficacy and metabolic stability of epoxyketones with previously underexplored P1′
substituents that can overcome both de novo and acquired Cfz resistance.
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CHAPTER 5. A SELECTIVE INHIBITOR OF THE IMMUNOPROTEASOME SUBUNIT
LMP2 ATTENUATES DISEASE PROGRESSION IN MOUSE MODELS OF
ALZHEIMER’S DISEASE

Some of the work in this chapter has been submitted to Nature Chemical Biology.
5.1 Introduction

Alzheimer’s disease (AD), the most common form of dementia, is a

degenerative disorder of the brain that leads to memory loss. AD is a progressive,

neurodegenerative disorder and is the sixth-leading cause of death across all ages.
Currently there is there is no cure for AD, however, promising research and
development for early detection and treatment is underway. Over the past decades,

new therapeutic approaches targeting amyloid-β (Aβ) have been discovered and
developed with the hope of modifying the natural history of AD. However, none of
these drugs resulted in the positive cognitive improvement in most recent highprofile phase III clinical trials [171], raising the doubt about amyloid hypothesis. In

addition to extracellular Aβ, intraneuronal neurofibrillary tangles (NFT) composed of
hyperphosphorylated tau protein have been also identified as a major hallmark of AD,

leading active development of AD therapies targeting tau aggregation. Unfortunately,
anti-tau therapies are also not available yet [291]. Therefore, it is highly timely and

important to design disease-modifying drugs that are not reliant on the amyloid or
tau hypothesis and to validate their therapeutic potential in pre-clinical and clinical
studies.

The 26S proteasome, an evolutionarily-conserved multiprotease complex, is

largely responsible for controlled degradation of intracellular proteins, ranging from
defective ribosomal products (DRiPs) to signaling proteins regulating numerous

cellular processes (e.g., cell cycle control, immune response, apoptosis, stress
response)[292]. Once poly-ubiquitinated, substrate proteins are recognized by the
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19S regulatory particle and degraded by the 20S core particle of the 26S proteasome.

In response to cellular stress or pro-inflammatory cytokines such as TNF-α or

interferon (INF)-γ, cells upregulate variant forms of proteasome catalytic subunits,
known as immuno-subunits (β1i/LMP2, β2i/MECL-1, β5i/LMP7). The resulting

immunoproteasome (IP) harbors the immuno-subunits LMP2 and MECL-1 and LMP7
instead of constitutive counterparts Y, Z and X, respectively.

A previous study demonstrating the depletion of immunoproteasomes

showed major changes in antigen presentation, indicating a fundamental role of the

IP in antigen presentation by major histocompatibility complex (MHC) I class [293].

In addition, the IP also manages oxidative stress via degradation of misfolded and

oxidant-damaged proteins [45]. In addition, LMP7, an immunoproteasome subunit,
has been considered as an attractive therapeutic target for autoimmune disease due

to the ability of regulating pro-inflammatory cytokine production in human tissues

(T-cells, B-cells, neutrophils, monocytes etc)[52-57, 80]. LMP7-selective inhibitors
(ONX0914, KZR-616) are currently in early phase clinical development for the

treatment of rheumatic diseases, such as lupus nephritis (LN). For LMP2, there have
been a few reports suggesting its involvement in processing of NFκB precursors

(p100/p105) and degradation of IκBα [58-60]. However, recent studies dispute the
involvement of LMP2 in inflammatory responses [56, 294 295].

Increasing evidence support an important role of inflammation in AD, thus

many efforts to develop anti-inflammatory drugs targeting inflammation yielded
several COX or TNF-α inhibitor for AD treatment. However, there is no clinically

available AD therapies relied on inflammation so far [190]. While the role of IP in

neuroinflammation is not clearly understood, it has been observed the elevated

expression and activity of IP is correlated with enhanced microglial activation in AD
patients and in a mouse model of brain injury [240-243]. Most recently, Wagner et al.
reported LMP7 knockout improved cognitive impairment in a mouse model of Aβ

deposition through altering microglial cytokine production profiles, suggesting a
potential role of IP in Aβ-induced neuroinflammation [51]. In addition, moderate up-

regulation of LMP2 expression in AD patients was also reported [244]. Despite these
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data suggesting the involvement of IP in neuroinflammatory responses and

therapeutic potential for AD treatment, the pharmacological inhibition of LMP7 or

LMP2 has never been tested for the impact on AD pathology.

In this study, we investigated the effect of LMP2 inhibition on the symptom of

AD, cognitive dysfunctions, in two different AD mouse models, LPS-induced

inflammation model and APP transgenic mouse model. We found that a peptide
epoxyketone inhibitor YU102 targeting LMP2 improved cognitive function in both of

AD mouse models. These results were not affecting Aβ deposition or tau aggregation

in a mouse model. Our in vitro cell line model data also showed YU102 suppresses

production of pro-inflammatory cytokines. In summary, YU102 improves cognitive
dysfunction by inhibiting pro-inflammatory cytokine production in microglial cells

and these findings suggest that LMP2 may offer a valuable therapeutic target for AD
treatment.

5.2 Material and Methods

5.2.1 Cells
BV-2, EOC BV-2, EOC-20, and WI-38 cells were seeded at 5,000 cells/well and RPMI
8226 cells. The murine microglial BV-2 cell line was a kind gift of Dr. Jin Tae Hong

(College of Pharmacy, Chungbuk National University, Korea). The murine microglial

cell line EOC-20, a human myeloma cell line RPMI 8226, and a human lung fibroblast
cell line WI-38 cell line were obtained from American Type Culture Collection. BV-2

cells were cultured in DMEM containing 10 % fetal bovine serum, and 1 mM pyruvate.
All other cells were cultured according to the manufacturer’s protocol in 5% CO2 in

medium. Cultured cell lines were tested for Mycoplasma contamination routinely

every 2 months. BV-2 cells or EOC-20 cells were seeded at 2.5 × 105 cells/mL in 12103

well plates and were activated by incubation in medium containing 1 µg/mL of E. coli

055:B5 lipopolysaccharide (Thermo Scientific).
5.2.2 Animals

For YU102 efficacy studies, 9-month-old Tg2576 and 8-week-old ICR mice were

purchased from the Division of Laboratory Animal Resources (Korea FDA, Osong,
South Korea) and Samtako (Osan, South Korea), respectively. All animal studies were
approved by Animal Care and Use Committee (IACUC) of Chungbuk National

University (approval number: CBNUA-144-1001-01). Animals were housed three per
cage, allowed access to water and food ad libitum, and maintained on a 12-h

light/dark cycle regulated at 23°C. Experiments were performed at least 1 week after
their arrival in individual home cages.
5.2.3 Animal behavioral analysis
5.2.3.1 The Morris watermaze test
The Morris water maze test was performed following a procedure described

previously [296]. Briefly, a circular plastic pool was filled with water maintained at

22-25℃. An escape platform was submerged 1-1.5 cm below the surface of the water.
The learning trials were conducted over 5 days, with three randomized starting
points. The position of the escape platform was kept constant. Each trial lasted for 60

sec or ended as soon as the mice reached the submerged platform. Swimming pattern

of each mouse was monitored and recorded by a camera mounted above the center
of the pool, and the escape latency, escape distance and swimming speed were

assessed by the SMART-LD program (Panlab, Spain). A quiet environment and
constant water temperature were maintained throughout the experimental period.
To assess memory consolidation, a probe test was performed 24 hr after the water

maze test (i.e. Day 6). For the probe test, the platform was removed from the pool and
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mice were allowed to swim freely. The swimming pattern of each mouse was
monitored and recorded for 60 sec using the SMART-LD program. Consolidated

spatial memory was estimated by the time spent in the target quadrant area.
5.2.3.2 The passive avoidance test

The passive avoidance test was performed 48 hours after the probe test. The passive
avoidance response was determined using a “step-through” apparatus (Med

Associates Inc., Vermont, USA) that is divided into an illuminated compartment and a
dark compartment (each 20.3 × 15.9 × 21.3 cm) adjoining each other through a small

gate with a grid floor, 3.175-mm stainless steel rods set 8 mm apart. On the first day
(i.e. Day 7), the mice were placed in the illuminated compartment facing away from

the dark compartment for the learning trial. When the mice moved completely into
the dark compartment, it received an electric shock (0.45 mA, 3 s duration). Twenty-

four hours after learning trial (i.e. Day 8), each mouse was placed in the illuminated
compartment and the latency period until the animal entered the dark compartment
was determined and defined as the step-through latency (i.e. Testing trial). The cutoff time for the examination was 180 seconds.
5.2.4 Tissue extraction from Tg2576 mouse
The hippocampus was dissected from parasagittal brain slices; nucleus accumbens
(NAc) and striatum were dissected from coronal brain slices; the ventral tegmental

area (VTA) was dissected from horizontal brain slices. Tissues were homogenized in
RIPA buffer (containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM MgCl2, 1 mM
EDTA, 1% Triton X-100, 0.25% sodium deoxycholate, 0.1% SDS, 1 mM sodium
orthovanadate, 5 mM β-glycerophosphate, 5 mM NaF and protease inhibitor cocktail),

sonicated and incubated on ice for 30 min. The samples were then centrifuged at
14,000g for 20 min and protein concentrations of the supernatant were determined
by the Bradford method.
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5.2.5 Proteasome activity assay
5.2.5.1 Using the purified human 20S proteasome
Purified 20S human proteasomes (from Boston Biochem) were used to assess the in
vitro activity of proteasome inhibitors. In 96-well format, 20S proteasomes (0.5

μg/mL) were mixed with proteasome inhibitors in assay buffer (20 mM Tris-HCl, 0.5

mM EDTA, 0.035% SDS) at room temperature for 30 min, prior to the addition of

fluorogenic substrates to a final assay volume of 100 μL. Fluorogenic substrates used
in this study are: Suc-LLVY-AMC (CT-L activity, 100 μM), Ac-PAL-AMC (LMP2, 100

μM), Ac-WLA-AMC (β5, 20 µM), Ac-nLPnLD-AMC (β1,100 µM), and Ac-ANW-AMC (β5i,
100 µM). The fluorescence of liberated AMC was measured over a period of 90 min at
360 and 460 nm on a SpectraMax M5 fluorescence plate reader (Molecular Devices).
5.2.5.1 Using the isolated mouse tissue samples
To measure proteasome activity in brain tissues isolated from Tg2576 mice, tissues
were homogenized in RIPA buffer (50 mM Tris Cl, pH 7.4, 150 mM NaCl, 5 mM EDTA,

1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, 1% aprotinin, 50 mM NaF) and
sonicated. Samples were then centrifuged for 20 min at 14,000g (4 °C). After the

Bradford protein assay of the supernatant, samples were loaded onto a 96-well plate

prior to the addition of the substrate (Ac-PAL-AMC) at 37 °C. Fluorescence was
recorded for 90 min using a Synergy-HT (Bio Tek) plate reader. To exclude nonproteasomal substrate degradation, control samples were incubated with YU102 (1

μM) for 60 min at 37 °C before loading on the plate and values were subtracted from
lysates incubated with DMSO control.
5.2.6 Immunoblotting analysis
Total cell lysates containing equivalent protein content were separated by 12% SDS-

PAGE and transferred to polyvinylidene difluoride membranes (Millipore) via a semi106

dry transfer. Membranes were then blocked in 5% non-fat dry milk (Bio-Rad) in Tris-

buffered saline with 0.05% Tween-20 (TBST) for 1 h at room temperature. After 5
times wash with PBS, membranes were probed with primary antibodies (anti-LMP2,

anti-LMP7, and anti- β-actin, Abcam) in 3% BSA followed by a rabbit horseradish
peroxidase-conjugated secondary antibody (GE Healthcare). β-actin was used as a gel
loading control. SuperSignal West Femto Chemiluminescent Substrate (Thermo
Scientific) and X-ray film (Thermo Scientific) were used for visualization.

5.2.7 Measurement of Aβ
Hippocampal Aβ1-42 levels were determined using an ELISA Kit (Cusabio Biotech Co.,

Ltd., Wilmington, DE, USA). Experiments were performed according to the
manufacturer’s instructions. In brief, samples and standards were added into the pre-

coated plate and incubated for 2 hours at 37℃. Biotinylated antibodies (1x) were

added to each well and incubated 1 hour at 37℃. After washing, HRP-avidin (1x) was

added and incubated for 30 minutes at 37℃. After washing, TMB substrate was added

to each well. After the addition of stop solution, the absorbance was measured at 450
nm using a microplate reader (Sunrise™, TECAN, Switzerland).
5.2.8 Thioflavin T staining
Frozen hippocampal tissues were cut into 30 μm sections by using cryostat
microtome (Leica CM1850; Leica Microsystems). The pieces of tissues were

thoroughly washed with distilled water for 5 min, and then transferred to gelatin

coated slides and placed in 1% Thioflavine T for 5 min, followed by dehydration using
ascending grades of ethanol (50%, 70%, 90%, and 100%) for 2 min in each grade. The

dehydrated samples were then mounted with mounting medium (FluoromountTM,
Sigma). Thioflavin T staining was examined by using a fluorescence microscope.
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5.2.9 Cresyl violet staining
Frozen hippocampal tissues were cut into 30 μm sections by using cryostat

microtome (Leica CM1850; Leica Microsystems, Korea). The pieces of tissues were
thoroughly washed with PBS to remove excess fixative agent, and then transferred to
gelatin coated slices and stained with 0.1% Cresyl violet (2-5 minutes) to identify

cortical layers and cytoarchitectural features of isocortical region. Next, the resulting
sections were washed with distill water and dehydrated by using ascending grades of

ethanol (50%, 70%, 90%, and 100%) for 2 min in each grade followed by a 1-min

immersion in a 1:1 mixture of absolute alcohol and xylene. The sections were then
rinsed with xylene for 5-10 min and mounted with mounting medium (CYTOSEALTM

XYL; Thermo Scientific, USA). The same areas of tissues were photographed (100x).
5.2.10 Tau aggregation assay

For microscopic image analysis, cells were plated in a black transparent 96-well plate.
The next day, tau-BiFC cells were treated with the okadaic acid or forskolin at various

concentrations. After, 2, 9, 19, and 24 hr of incubation, the entire 96-well plate was
automatically imaged under same exposure by using Operetta® High Contents
Screening System (equipped with a 10x and 20X dry lenses). The cellular intensities

of tau-BiFC fluorescence were analyzed using Harmony 3.1 software. Error bars
indicate s.d. from two independent experiments. Each experiment was performed as
triplicate.

5.2.11 Immunohistochemical staining
Frozen hippocampal tissues were cut into 30 μm thick sections and stored free
floating in cryoprotectant solution (30% ethylene glycol, 20% glycerol, 50 mM

sodium phosphate buffer, pH 7.4) at 4 °C until further use. For immunohistochemical
staining, sections were rinsed in 1× PBS, incubated in blocking buffer (1× PBS
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containing 0.3% Triton X-100 and 10% normal goat serum) for 1 hr at room

temperature and further incubated overnight with primary antibodies for GFAP
(1:1000; Abcam) or Iba-1 (1:500; Abcam) diluted in 1× PBS/ 0.3% triton X-100/ 5%

normal goat serum at 4 °C. Sections were washed with 1× PBS to remove excessive

primary antibodies, incubated with species specific peroxidase-coupled secondary
antibodies (goat anti-mouse or goat anti-rabbit (1:300, Abcam)) diluted in 1× PBS/

0.3% Triton X-100/ 5% normal goat serum. The resulting sections were incubated
for 1 h on a shaker at RT and developed with liquid diaminobezadine (DAB) (Dako,
K3647). Sections were then counterstained with matured hematoxylin, followed by

dehydration in an ascending alcohol series before covering using Roti®-Histokitt II

mounting medium. For Congo red staining, free-floating cerebral sections were
mounted on glass slides and incubated in stock solution I (0.5 M NaCl in 80% ethanol,
1% NaOH) for 20 min and subsequently stock solution II (8.6 mM Congo red in stock

solution I, 1% NaOH) for 45 min. After rinsing twice in absolute ethanol, sections were
counterstained with mature hematoxylin and dehydrated in ascending alcohol series

before rinsing twice in 98% xylene for 1 min, and finally mounted with Roti®Histokitt II mounting medium. Stereological analysis was performed using a Stereo
Investigator system (MicroBrightField) and DV-47d camera (MicroBrightField)

mounted on an Olympus BX53 microscope (Olympus, Germany). Fluorescence

imaging was performed using an Olympus XM10 monochrome fluorescence CCD
camera (Olympus, Germany).

5.2.12 Membrane-based cytokine array
A cytokine antibody array assay was performed with a mouse cytokine array kit (R&D

Systems) according to the manufacturer’s protocol. Briefly, BV-2 cells, seeded in a 12-

well plate at 2 x 105 cells per well, were incubated with 1 µg/mL of E. coli 055:B5
lipopolysaccharide (Thermo Scientific) and 3 µM of YU102 or ONX 0914 for 24 hr.

The supernatants from BV-2 cells were collected and centrifuged to remove cell

debris. The resulting supernatants were then incubated with assay membranes
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precoated with capture antibodies overnight at 4°C. After rinsing the membranes

with wash buffer, a detection antibody was added using streptavidin–horseradish
peroxidase (HRP) and Chemi Reagent Mix. The immunoblot images were visualized
using SuperSignal West Femto Chemiluminescent Substrate (Thermo Scientific) and
X-ray film (Thermo Scientific or GeneMate).

5.2.13 Enzyme-linked immunosorbent assay (ELISA)
BV-2 microglial cells (2.5 × 105 cells/well) were seeded in 12-well culture plates. After

overnight incubation, cells were simultaneously treated with 1 µg/mL of E. coli LPS
and various concentrations of YU102, YU102 epimer, or ONX 0914 for 24 h.
Supernatants were analyzed for the quantification of released pro-inflammatory

cytokines, using Mouse IL-1α, IL-6, or CCL12/MCP-5 uncoated sandwich ELISA Kit
(Thermo Scientific) on high-binding ELISA plates according to the manufacturer’s

protocol. Briefly, standards and samples were incubated on capture antibody coated
plate for 2 h at room temperature, followed by incubation with detection antibody for

1 h and then Avidin-HRP for 30 minutes. For visualization, substrate solution was
added to each well, and then the reaction was stopped by the addition of stop solution
(2N H2SO4). Absorbance was measured by ELISA microplate reader at 450 nm
wavelength.

5.2.14 RPE flat mounts
Retinal pigment epithelium (RPE) of Tg2576 was isolated and incubated with β-

catenin (1:100 diluted) overnight at 4°C. After incubation with primary antibody, the

RPE tissues were further incubated with Alexa 555-conjugated secondary antibody

(Invitrogen; A21422; 1:1000 diluted) at room temperature for 2 hours. Sample was
observed by using a confocal microscope (Carl Zeiss, LSM 800)
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5.2.15 Cell-based RPE degeneration assay
ARPE-19 cells were seeded at 80,000 cells/well in 24-well plate with auto-coverglass.
Cells were treated with 50 ng/mL of TNF-α and incubated for additional 24 hr before

treatment with vehicle, 1 μM of YU102 or YU102 epi. After incubation, cells were fixed

with 4% paraformaldehyde for 1 h at room temperature. Cells were then blocked with
3% BSA for 1 h after permeabilized with 0.2% Triton X-100 for 15 min. Cells were

incubated overnight at 4°C with the primary antibodies (1:100; E-cadherin; Abcam;

ab1416, 1:100; Vimentin; Abcam; ab92547) and treated with the fluorescenceconjugated secondary antibodies (1:1000; Alexa Fluor 488 and 555) for 2 h at room

temperature in the dark. The cells were washed 3 times with PBS for 10 min each
after every step, and the nuclei were stained with DAPI (1:1000; Invitrogen, D1306).

Cells were mounted on the coverslip with ProLong Gold antifade reagent (Invitrogen

Life Technologies, P36934) and observed with a confocal microscope (Carl Zeiss,
LSM800).

5.2.16 Cell viability assay
BV-2, EOC-20, and WI-38 cells were seeded at 5,000 cells/well and RPMI 8226 cells

were seeded at 10,000 cells/well in 96-well plates. Following overnight incubation,

cells were treated with carfilzomib, ONX0914 or YU102 at indicated concentrations

for 72 h. Cell viability was determined by CellTiter 96 AQueous One Solution Cell

Proliferation assay (Promega) following manufacturer’s protocol. Absorbance at 490
nm was measured using a SpectraMax M5 microplate reader (Molecular Devices).
5.2.17 Statistics
Results are expressed as means ± S.D. Statistical significance of the observed group
differences was determined using Student’s t-test or two-way ANOVA followed by
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Dunnette’s post hoc test. Significance was set at p < 0.05 for all tests. All statistical
analyses were carried out using GraphPad Prism 8.0.1 (GraphPad Software).
5.3 Results

5.3.1 YU102 improves cognitive function in an LPS-induced mouse model of
neuroinflammation

Since previous data suggested an increase in iP gene expression during aging

and in plaque-associated glia cells in APP/PS1 mice we examined the impacts of

proteasome inhibition on cognitive impairments using several subunit-selective

proteasome inhibitors [240] (Figure 5.1A). We first ensured that cP or iP selective

inhibitors displayed the expected inhibitory profile by conducting proteasome
activity assays with subunit-selective fluorogenic substrates in purified human 20S

constitutive and immunoproteasomes (Figure 5.1B). We set out to examine whether
inhibition of IP activity might reduce or eliminate cognitive impairments caused by

AD. For an initial assessment, we chose to use a lipopolysaccharide (LPS)-induced

inflammation mouse model, known to display AD-like cognitive impairment [297,

298]. Specifically, 8-week old ICR mice were treated with daily injections of LPS for 5

days (250 µg/day), followed by i.p. delivery of iP-selective YU102 (10 mg/kg), PR-

924 (10 mg/kg), CP-selective PR-825 (2 mg/kg) or conventional PIs (carfilzomib

5mg/kg, bortezomib 1 mg/kg) twice a week for 3 weeks. At the end of treatment

period, the Morris water maze test was performed to evaluate cognitive functioning
in mice. All mice were trained three times on the same day prior to daily

measurements of escape latency and distance traveled over 5 consecutive days. Of

note, none of the tested mice displayed any irregularity in their motility.
Unfortunately, almost all the mice treated with general PIs (carfilzomib, bortezomib;
inhibit both CP and IP) did not survive to complete the test. In contrast, the mice
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treated with YU102 displayed no signs of overt toxicity and exhibited improved
distance and escape latency compared to mice treated with LPS alone. Mice treated
with PR-825 (X-selective) or PR-924 (LMP7-selective) displayed only mild
improvement in performance relative to LPS-treated control mice (Figure 5.2 A&B).

Next, we conducted probe trials to measure the ability of memory. As shown in Figure
5.2C, YU102-treated group displayed the better performance, spending longer time

in the target quadrant compared to the control groups. One day after the probe tests,
we performed the passive avoidance assay by measuring an average step-through
latency of YU102-treated group or control groups (vehicle only or LPS treated group)

(Figure 5.3). Consistent with previous the Morris water maze assay data, YU102
treated group showed the improved performance compared to LPS-treated group.

This result was intriguing in that LMP2 inhibition through pharmacological inhibition
or genetic knockout of LMP2 previously showed no effect on proinflammatory

cytokine release from LPS-stimulated human PBMCs or mouse peritoneal
macrophages [56, 294]. Taken together, we suggested that IP inhibition, especially

LMP2 inhibition could improve cognitive impairment caused by a LPS-induced

neuroinflammation.
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A

B

Figure 5.1 Structures and Proteasome inhibitory activity of PIs
A. structures of immunoproteasome inhibitors (YU102, PR-924), YU102 epimer (an

inactive stereoisomer of YU102), and constitutive proteasome inhibitor (PR-825) are

shown. B. Proteasome inhibitory activity profiles of YU102, YU102 epimer, PR-924,

and PR-825 in human purified 20S proteasome are shown. Data is shown as mean ±

SD derived from a non-linear regression based on n=3 replicates per compound per
concentration. aIC50 values were determined from competition assays in Raji cell

lysates [84]. bIC50 values were approximated from ProCISE assay using A20 murine

lymphoma cells [52]. cIC50 values were from ProCISE ELISA using MOLT-4 human

leukemia cells [332].
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B

C

Figure 5.2 The Morris water maze tests in LPS-induced mouse model
YU102 (10mg/Kg), PR-924 (10mg/kg), PR-825 (2mg/kg), carfilzomib (5mg/kg) and

bortezomib (1mg/kg) were treated in LPS-induced mouse model. Mice treated
carfilzomib or bortezomib could not survive. Escape latency time in the target

quadrant (A) and escape distance (B) of the mice were shown. Statistical analysis was

performed via two-way ANOVA. *Differences in escape latency on days 4-6 and
distance on day 6 between LPS-treated and YU102 treated were statistically

significant (p-value < 0.05, n=5). C. Tg2576 mice were evaluated in the probe trial.
(This experiment was performed by In Jun Yeo from Dr. Jin Tae Hong’s group in the
college of Pharmacy, Chungbuk National University, Korea)
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Figure 5.3 The passive avoidance test in LPS-induced mouse model
One day after the probe trials, LPS-induced mice were evaluated in passive avoidance

test among vehicle only, LPS-injected (250 µg/day, for 5days), or LPS injected and
then YU102-treated group (10mg/kg, twice a week for 3 weeks). (This experiment

was performed by In Jun Yeo from Dr. Jin Tae Hong’s group in the college of Pharmacy,
Chungbuk National University, Korea)
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5.3.2 YU102 ameliorates AD-related cognitive impairment in the Tg2576 mouse
model

Encouraged by our initial assessment showing the promising activity of YU102

in a mouse model of LPS-induced inflammation (Figures 5.2 and 5.3), we wanted to

further verify its efficacy using a more relevant animal model of AD. To this end, we
chose the APP transgenic mouse model (also known as Tg2576), which exhibit ageassociated deficits in learning and memory with Aβ deposits as a result of expression

of KM670/671NL mutant human APP. To demonstrate target engagement and
specificity of YU102, an inactive stereoisomer of YU102 (YU102 epi, a negative

control) were also included. First, 10-month old APPsw mice (Tg2576 mice) were
treated with YU102 via the intraperitoneal (i.p.) twice a week for 3 weeks and then

the Morris water maze test was performed, followed by a single probe trial 24 hours
later o and passive avoidance test to investigate the impacts of YU102 treatment on

spatial learning and memory in a Tg2576 mouse model. Specifically, all mice were
trained for three times for 5 days before behavior investigation. Initially, escape

latency and distance traveled were measured on a daily-basis over a 5-day period.

Remarkably, as shown in Figure 5.4, consistent with the results obtained from the

LPS-induced inflammation model, mice treated with YU-102 exhibited significantly
shorter distance and escape latency than those treated with inactive YU102 epi or

vehicle (Figure 5.4 A & B). This strongly supports that the efficacy of YU102 is
mediated through LMP2 inhibition. One day after the Morris water maze test, we next
measured the ability of mouse to maintain memory on probe trials. In line with the

results from the water maze tests, YU102-treated mice performed significantly better
than control groups: the percentage of time spent in the target quadrant was 21.25 ±
2.71% for YU102-treated group and ~10-14.50 ± 1.03% for control groups (Figure

5.4C). Sequentially, a step-through latency test was performed a day after the probe
trial. While Tg2565-vehicle treated group showed an average step-through latency of
~44 sec, YU102-treated group had ~128 sec, displaying considerably improved fear117

associated short-term memory, suggesting LMP2 activity improves cognitive function
in Tg2576 mice (Figure 5.5).
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B
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Figure 5.4 The Morris water maze tests in Tg2565 mice
YU102 ameliorates cognitive deficits in Tg2576 mice. Escape latency time in the

target quadrant (A) and escape distance (B) were shown. Statistical analysis was
performed via two-way ANOVA. *Difference in escape latency on days 4-5 or distance

on days 3-5 between control and YU102-treated mice was statistically significant (p-

value < 0.05, n=8). C. Upon the completion of the Morris water maze test, Tg2576 mice

were evaluated in the probe trial. Statistical analysis for probe trial was performed
via Student-t test. Differences in time spent in target quadrant between control and

YU102-treated mice were statistically significant (p-value < 0.05, n=8) (This

experiment was performed by In Jun Yeo from Dr. Jin Tae Hong’s group in the college
of Pharmacy, Chungbuk National University, Korea)
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Figure 5.5 The passive avoidance test in Tg2576 mice
One day after the probe trials, Tg2565 mice were evaluated in passive avoidance test
between vehicle only and YU102-treated group (10mg/kg, twice a week for 3 weeks).

Statistical analysis for passive avoidance was performed via Student-t test. Difference
in step through latency between control and YU102-treated mice were statistically
significant (p-value < 0.05, n=8) (This experiment was performed by In Jun Yeo from

Dr. Jin Tae Hong’s group in the college of Pharmacy, Chungbuk National University,
Korea)
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5.3.3 YU102 selectively inhibits LMP2 activity in the Tg2576 mouse model
After behavioral testing, mice were sacrificed and proteasome activities in

different organ tissues were measured to examine target engagement and specificity
of YU102 by measuring the remaining LMP2 activity in mice. As shown in Figure 5.6,

YU102 inhibited LMP2 but not Y or LMP7/X-associated proteasome activity
(measured as the CT-L activity). This target engagement investigation was possible

due to the irreversible covalent binding of YU102 to LMP2. It should be also noted
that the family of peptide α,β-epoxyketones such as YU102 have been shown to be

highly selective for the proteasome with no significant off-targets reported so far 44-

48. As such, we expect that YU102 will likely have no major off-target interactions.
The relatively modest LMP2 inhibition observed in monitored tissues is likely due to
the synthesis of new proteasome catalytic subunits during the gap between the final

YU102 treatment and sacrifice. Taken together, the results support that selective
inhibition of LMP2 activity improves cognitive function in the APP transgenic mouse
model of AD.
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Figure 5.6 The proteasome activities in organ tissues collected from Tg2565
mice
Upon the completion of the behavior test, proteasome activities in heart and lung
collected from Tg2576 mice treated with vehicle, YU102 (10 mg/kg), or YU102
epimer (10 mg/kg) were measured using fluorogenic substrates. Error bars are
standard deviation derived from three technical replicates. *Differences in LMP2

inhibitory activity in spleen, liver, heart, and lung tissues between YU102-treated and
YU102 epi-treated group were statistically significant (p-value < 0.05, n=3).
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5.3.4 YU102 exerts its efficacy independently of Aβ deposition
Given the data showing improved learning and memory of LMP2 inhibitor-

treated mouse models of AD, we initially suspected that YU102 exert their activity by

promoting Aβ clearance in the brain of Tg2576 mice via an undefined mechanism. To
examine such a possibility, we measured the levels of soluble Aβ in hippocampal
tissues isolated from the brain of Tg2576 mice using an enzyme-linked

immunosorbent assay (ELISA) and levels of amyloid fibrils were measured via the
fluorescent dye Thioflavin T. Interestingly, we observed no difference in Aβ
deposition between the mice treated with YU102 and vehicle-treated mice (Figure

5.7 A & B). The results can be cautiously interpreted that YU102 may exert its anti-

AD efficacy in the Tg2576 model independently of Aβ deposition or clearance. This
result is highly intriguing considering that several drugs with proven Aβ-clearing
ability have failed to demonstrate clinically meaningful efficacy in recent high-profile

phase 3 clinical trials [171].
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A

B

Figure 5.7 Efficacy of YU102 in Tg2576 mice on Aβ deposition
A. ELISA-based quantification of Aβ1-42 in hippocampal tissues isolated from Tg2576

mice. The difference in the levels of Aβ1-42 between vehicle control and YU102-treated

mice was not statistically significant (p-value > 0.1, n=3). Statistical analysis of ELISA

results was performed via Student t-test. B. Thioflavin T staining of Aβ fibrils in
hippocampal tissue sections from Tg2576 mice. (This experiment was performed by

In Jun Yeo from Dr. Jin Tae Hong’s group in the college of Pharmacy, Chungbuk
National University, Korea)
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5.3.5 Efficacy of YU102 is unrelated to tau or neuroprotection
5.3.5.1 Effect of YU102 on Tau aggregation

Tau polymerization has been considered as one of main culprits behind AD

etiology and a potential target for therapeutic intervention [299]. In Tg2576 mice,

hyperphosphorylated tau oligomerizes in an age-dependent manner that coincides
with the appearance of Aβ oligomers and declining cognitive function [300-304].

Given this, we wondered whether YU102 exerts its anti-AD efficacy by inhibiting the

oligomerization of hyperphosphorylated tau. To quickly test this possibility, we used
HEK293-tau-BiFC (bimolecular fluorescence complementation) cell-based assay, in

which tau oligomerization and aggregation induced by an activator of protein kinase

A (PKA) such as forskolin or thapsigargin can be detected via the reconstitution of the

fluorescent protein Venus. As shown in Figure 5.8, YU102 did not inhibit thapsigargin

or forskolin-induced tau aggregation. Low tau-BiFC intensity observed at high
concentration of LMP2 inhibitors (30-100µM) were due to cell death. Taken together,
these results demonstrate that the YU102-induced improvement in cognitive
behavior in Tg2576 mice is independent of Aβ deposition and tau aggregation.
5.3.5.2 Effect of YU102 on neuroprotection

Since accumulation of misfolded proteins such as Aβ in cells induces immune

response and cell death, we next tested whether YU102 has neuroprotective effects

in Tg2576 mice. To examine this, we performed Cresyl violet staining experiments on
neuronal tissues isolated from the brains of Tg2576 mice. We found no noticeable

difference in the total number of neurons between mouse groups treated with YU102,
YU102 epi, or vehicle (Figure 5.9). Although we found no evidence that YU102 affects
neuron survival, these results could also be affected by the relatively short drug
treatment period (~3 weeks).
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Figure 5.8 Efficacy of YU102 in Tg2576 mice on tau aggregation
YU102 has no effect on tau aggregation. Thapsigargin (1µM) or forskolin (1µM)
induces tau aggregation in tau-BiFC cells, activating a tau BiFC fluorescence signal
that can be detected. (This experiment was performed by Hyun Jung Jeong from Dr.
Yun Kyung Kim at KIST, Korea.)
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Figure 5.9 Efficacy of YU102 in Tg2576 mice on neuroprotection
YU102 displays no neuroprotective effects during the experimental period.

Hippocampal tissues isolated from the brains of Tg2576 mice were stained with
Cresyl violet, a marker for Nissl substance in neurons. (This experiment was
performed by In Jun Yeo from Dr. Jin Tae Hong’s group in the college of Pharmacy,

Chungbuk National University, Korea.)
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5.3.6 YU102 reduces the number of reactive astrocytes and microglia in Tg2576 mice
Neuroinflammation is reported to be closely linked to the development and

progression of AD and inflammation in the brain is characterized by the activation of

neuroglia cells (microglia and astrocytes), which was considered as a major culprit

behind AD pathology and a key drug target in neurodegenerative diseases [249, 305-

307]. Also, Aβ and LPS have been shown to distinctly alter cytokine production

profiles and induce innate immune signaling and microglial activation [308-311].

Therefore, we set out to investigate whether YU102 blocks the activation of glial cells

in brain tissues of Tg2576 mice. When immunostaining for GFAP and Iba1, known
markers of reactive astrocytes and microglia, respectively, was performed, we

observed that the numbers of positively stained cells in hippocampal tissues were
significantly fewer in mice treated with YU102 than in the control group (Figure
5.10A). COX-2 also known as a proinflammatory enzyme is overexpressed in human

AD and mouse AD models [312-314]. As shown in Figure 5.10B, expression of COX-2

was also significantly lower in hippocampal tissues of mice treated with YU102
compared to control mice. Taken together, these data suggest that LMP2 is involved
in the activation of glia cells and that LMP2 inhibition suppresses activation of
astrocytes and microglia and thus suppresses neuroinflammation.

128

A

B

Figure 5.10 YU102 reduces the numbers of activated astrocytes and microglia
A. Reactive astrocytes (left) and microglial cells (right) were visualized using
respective markers (GFAP and Iba1) in hippocampal tissues from Tg2576 mice. B.

Expression levels of COX-2 in hippocampal tissues in Tg2576 mice treated with

YU102 are lower than in the control Tg2576 mice. (This experiment was performed
by In Jun Yeo from Dr. Jin Tae Hong’s group in the college of Pharmacy, Chungbuk
National University, Korea)

129

5.3.7 LMP2 inhibition attenuates pro-inflammatory cytokine production in microglial
cells

5.3.7.1 Membrane-based cytokine array

It is well-documented that activated microglia synthesize and release pro-

inflammatory cytokines and play an important role in AD progression. Furthermore,
secretion of pro-inflammatory cytokines by microglia and associated changes in
phagocytic and neuroprotective properties are a major contributing factor to the

recently recognized “cellular” phase of Alzheimer’s disease [315, 316]. Since YU102

reduced the number of activated microglia cells in Tg2576 mice, we suspected that it
could exert their anti-AD efficacy by suppressing pro-inflammatory cytokine
production. Therefore, we examined whether YU102 can suppress the production of

pro-inflammatory cytokines in microglial cells. To do this, we used an immortalized
murine microglial cell line BV-2, commonly used as a substitute for primary microglia

in many experimental settings [317]. BV-2 cells were pre-incubated with YU102 for

2 hr before LPS treatment to upregulate cytokines. After additional 24 hr incubation,

cell supernatants were collected and analyzed for the levels of 40 cytokines and
chemokines using a membrane-based mouse cytokine antibody array (Figure 5.11A).

BV-2 cells treated with LPS only exhibited elevated levels of multiple pro-

inflammatory cytokines and chemokines compared to unstimulated cells (Figure 5.11
B & C). As previously reported, ONX 0914, a selective inhibitor of immuno-subunit

LMP7, suppressed LPS-induced production of pro-inflammatory cytokines, such as

IL-1β, CCL12/MCP-5, IL-6 and CCL5/RANTES [52]. Similarly, YU102 also significantly
attenuates production of IL-1α, CCL12/MCP-5, and to a lesser degree, IL-6 which were
induced by LPS. The result that YU102, a LMP2 inhibitor, strongly suppressed the

production of several proinflammatory cytokines was highly intriguing. Previously,
inhibitors of LMP2, such as KZR-504, displayed little to no suppression of cytokine
production (e.g. IL-1β, IL-6, IL-8, TNF-α) in human peripheral blood mononuclear

cells (PBMCs) [56]. We suspect these contradictory results are due to cell type
130

(organ)-specific role of LMP2, indicating a distinct role of LMP2 in microglia

inflammatory response. Altogether, these findings demonstrate that inhibition of
LMP2 ameliorates disease in mouse models of AD and may offer a promising strategy
for AD treatment.

5.3.7.2 Enzyme-linked immunosorbent assay (ELISA)
Since we observed the effect of YU102 on the production of pro-inflammatory

cytokines and chemokines in LPS-stimulated BV-2 microglial cells using a mouse

cytokine membrane array, we further verified the effect of YU102 on microglia

cytokine release in vitro by measuring the levels of individual cytokines in LPS-

stimulated BV-2 cells treated with vehicle or YU102 via enzyme-linked

immunosorbent assay (ELISA). Consistent with membrane-based cytokine array, as

shown in Figure 5.12, LPS-activated BV-2 cells secreted significantly increased
amounts of pro-inflammatory cytokines IL-α and IL-6 and mildly upregulated the
level of pro-inflammatory chemokine CCL12. Most notably, inhibition of LMP2 by

YU102 substantially attenuated the levels of IL-α, IL-6, and CCL12 production. Taken
together, our results suggest a specific role for LMP2 in modulating the glial response
during LPS-induced neuroinflammation.
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A

B

Figure 5.11 Mouse cytokine array in microglial BV-2 cells
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C

Figure 5.11 Mouse cytokine array in microglial BV-2 cells (continued)
Suppression of cytokine production by YU102 in LPS-stimulated BV-2 cells. A.

Cytokine and chemokine protein array blots of BV-2 cells treated with vehicle, LPS
(1µg/mL) alone, and YU102 (3µM) or ONX0914 (3µM) with LPS (1µg/mL). B. The

amount of each cytokine or chemokine was relative to the mean of the intensity of
corresponding spots from vehicle control sample. Each cytokine or chemokine has

duplicate detection spots. Graph depicts the fold change of each cytokine or

chemokine (mean). Arrow labels indicate cytokines that are most significantly
impacted by YU102. C. Full suppression profile of cytokine production by YU102 in
LPS-stimulated BV-2 cells using a mouse cytokine array kit (R&D Systems). The

amount of each cytokine or chemokine was relative to the mean of the intensity of
corresponding spots from vehicle control sample. Each cytokine or chemokine has

duplicate detection spots. The graph depicts the mean spot pixel density from the
arrays using Quantity One software (Bio-rad) analysis.
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Figure 5.12 Enzyme-linked immunosorbent assay (ELISA) in BV-2 cells
Cytokine production in LPS-stimulated BV-2 cells with and without YU102 was
determined by ELISA. Effect of YU102 on the release of cytokines in LPS-stimulated
BV-2 cells. BV-2 cells were incubated with LPS (1µg/mL) and YU102 or YU102 epimer

for 24 h. All values are expressed as mean ± SEM from three independent experiments.
*Differences in suppression of IL-1α and IL-6 levels between YU102-treated and
YU102 epi-treated group were statistically significant (p-value < 0.05, n=3).
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5.3.8 YU102 selectively inhibits LMP2 subunit in microglial cells
In line with selectivity data of YU102 in different organ tissues isolated from

Tg2576 mice after behavior test, we confirmed selective LMP2 inhibition by YU102
using microglial cell line model BV-2 cells. First, we conducted proteasome activity
assay with subunit-selective fluorogenic substrates in BV-2 cells. YU102 significantly
inhibits LMP2 subunit at low concentrations (0.1 and 0.3µM), while ONX0914, a

LMP7-selective inhibitor, achieved > 50% inhibition of both LMP2 and LMP7 activity
at 0.3µM concentration in BV-2 cells (Figure 5.13A). We next assessed the specificity

of YU102 toward the LMP2 subunit by mobility shift assays with western blot to

visualize the YU102-LMP2 covalent adduct (Figure 5.13B). For mobility shift assay,

where indicated, BV-2 cells were treated with DMSO, 0.1-3µM YU102 or YU102

epimer for 4 h. For competition assay, BV-2 cells were pre-treated with 1µM YU102
for 1 h, prior to the addition of the addition of 0.1-3µM YU102 epimer. The covalent
binding of YU102 to LMP2 is shown by a complete upward shift of the LMP2 band in

BV-2 cells upon treatment with YU102 compared to YU102 epimer. Conversely,
covalent modification of proteasome catalytic subunits LMP7 and X by YU102 was not

observed (data now shown). These results clearly showed that YU102 covalently

binds LMP2, but not the other catalytic subunits of proteasomes in BV-2 cells,

indicating its high specificity toward the LMP2 subunit.
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A

B

Figure 5.13 Selectivity of YU102 in BV-2 cells
A. Remaining catalytic activities of individual subunits in LPS-stimulated BV-2 cells 4

h after treatment with YU102 (top) or ONX0914 (bottom) at various concentrations.
Data are presented as mean ± SEM from three independent experiments. B.

Visualization of target engagement via immublotting YU102: LMP2 covalent adduct
on the SDS-PAGE. BV-2 cells were treated with YU102 for 1 h at 0.3, 1, or 3µM
concentrations.
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5.3.9 Broad impacts of YU102 on neuroinflammatory disorders in Tg2576 mice
Several recent studies demonstrated that Aβ deposits are consistently found

in the retina from patients with age-related macular degeneration (AMD) and can be
positively correlated with the disease progress [318]. In addition, it has been

reported that inflammation triggered by Aβ is a major contributor to RPE (retinal

pigment epithelium) abnormalities in APP transgenic animal models including
Tg2576 [319-321]. Given this, we investigated the effects of YU102 on RPE

degeneration in Tg2576 mice, a characteristic of age-related macular degeneration
(AMD) [318]. RPE samples were collected from Tg2576 mice treated with vehicle,
YU102, or YU102 epi and subjected to immunohistochemical staining with an anti-β-

catenin primary antibody followed by Alexa 555-conjugated secondary antibody. As
shown in top, Figure 5.14, the orderly mosaic structure of RPE typically observed in
non-transgenic mice was severely damaged in Tg2576 mice treated with vehicle only,

as previously reported [322]. However, YU102 provided Tg2576 mice with almost

complete protection from RPE damage, showing the typical mosaic structure of RPE

(middle, Figure 5.14). In contrast, YU102 epi (an inactive stereoisomer of YU102)
provided no protection from RPE mosaic disruption (bottom, Figure 5.14), indicating
that YU102 protected the structure integrity of retina from degeneration through
LMP2 inhibition.

5.3.10 The effect of YU102 on human RPE cells degeneration
In order to further verify in vivo observation in Figure 5.13, we conducted in

vitro studies using the human RPE cell line ARPE-19, known to form a mosaic-like
monolayer. Inflammatory stimuli, such as TNF-α, induce epithelial-to-mesenchymal

transition (EMT) with concomitant morphological and molecular changes in ARPE-

19. Normal ARPE-19 cells maintain the epithelial morphology and show high
expression of E-cadherin in cell-cell junction with little expression of Vimentin in the
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cytoplasm [323]. However, in response to TNF-α, ARPE-19 cells underwent EMT and

exhibited downregulation of E-cadherin and overexpression of Vimentin in the

cytoplasm. Notable, when the RPE cells were treated with LMP2 inhibitor, YU102,
TNA-α-induced EMT was significantly suppressed through the maintenance of E-

cadherin expression and inhibition of Vimentin expression (Figure 5.15). These

results suggest suppression of TNF-α-induced inflammatory response. These findings
are in line with a previous report that in response to TNF-α, RPE cells isolated from

LMP2 knockout mice exhibit diminished NF-κB activation [324]. In summary, the
result supports that LMP2 inhibition may control inflammatory response of RPE cells
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Figure 5.14 Effect of YU102 on in vivo RPE degeneration
YU102 inhibits in vivo RPE (retinal pigment epithelium) degeneration. RPE from eyes
of Tg2576 mice treated with vehicle, YU102 or YU102 epi were isolated and

immunostained to establish boundaries of RPE monolayers. (This experiment was
performed by Areun Baek from Dr. Dong Eun Kim’s group in the department of
Bioscience and Biotechnology, Konkuk University, Korea)
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Figure 5.15 Effect of YU102 on in vitro RPE degeneration
YU102 inhibits in vitro RPE degeneration. EMT in the human RPE cell line ARPE-19
was induced by TNF-α. TNFα-induced EMT in ARPE-19 cells was attenuated by

YU102 but not YU102 epimer. EMT is detected by upregulation of vimentin and

downregulation of E-cadherin. (This experiment was performed by Areun Baek from
Dr. Dong Eun Kim’s group in the department of Bioscience and Biotechnology,
Konkuk University, Korea)
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5.3.11 YU102 has no cytotoxic effect
It is critical that LMP2 inhibition leads no major adverse effects in the body for

the use of chronic AD therapy. Throughout our in vivo efficacy studies of YU102, we

observed no signs of overt toxicities in mice treated with YU102. To further verify the

non-toxicity of YU102 in cell culture, we incubated a panel of cell lines (WI-38, a

human lung fibroblast cell line; RPMI 8266, a human myeloma cell line; BV-2 and EOC20, two murine microglial cell lines) with YU102, ONX 0914 (an LMP7 inhibitor), or

carfilzomib (an FDA-approved inhibitor targeting multiple proteasome subunits

including β5 and β5i, a positive control known to induce cell death) for 2-3 days. We

then performed cell viability assays using CellTiter 96 AQueous One Solution. YU102

showed no negative impact on the viability of all four cell lines at relevant

concentrations (Table 5.1 and Figure 5.16). In comparison, ONX 0914 was much more

toxic to these cell lines than YU102 and has a low therapeutic margin. Intriguingly,
activation via LPS pretreatment further sensitized the two microglial cell lines (BV-2,

and EOC-20 cell lines) to ONX0914, not to YU102, which is in line with previous

reports demonstrating near complete cell death in a primary neuron model with 48
hours of 500 nM ONX0914 (Figure 5.16) [325]. Taken together, these results

potentially indicate that LMP2 inhibition may offer a safer therapeutic strategy for
neurodegenerative diseases than LMP7 inhibition.
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Table 5.1 Cytotoxicity of proteasome inhibitors in BV-2, EOC20, RPMI 8226,
and WI-38 cells
Cell viability (IC50, nM)
Inhibitor
Carfilzomib
ONX 0914
YU102

BV-2

EOC-20

RPMI8226

WI-38

1576.2
± 300.8

781.1
± 154.7

8.7
± 3.1

17.9
± 5.9

˃10,000

˃10,000

1,327
± 374.8

1030
± 552.3

154.1
± 23.4

˃10,000

682.7
± 66.4

˃10,000

Data is shown as mean ± SD derived from a non-linear regression based on n=3
replicates per compound per concentration
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Figure 5.16 Cell viability graphs for YU102, and ONX0914 in various cell lines
EOC-20 and WI-38 cells were seeded at 5,000 cells/well and RPMI 8226 cells were
seeded at 10,000 cells/well in 96-well plates. Following overnight incubation, cells

were treated with YU102 or ONX0914 at indicated concentrations for 48 h (EOC-20

with or without 24h 1µg/mL LPS pretreatment) or 72 h (RPMI 8266 and WI-38). Cell
viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation
assay (Promega) following manufacturer’s protocol. Absorbance at 490 nm was
measured using a SpectraMax M5 microplate reader (Molecular Devices).
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5.4 Discussion

Alzheimer’s disease is increasing rapidly in frequency as the world’s population

ages and more people enter the major risk period for this age-related disorder.
Current drug treatment for AD patients, essentially symptomatic, is based on three

cholinesterase inhibitors (rivastigmine, donepezil and galantamine) and memantine,

affecting the glutamatergic system. These drugs do not represent a cure, as they do
not arrest the progression of dementia, but rather, they lead to a temporary

slowdown in the loss of cognitive. In recent years, several drug candidates (either
monoclonal antibodies or small molecules) have been pursued based on the amyloid

hypothesis. However, none of these drugs displayed meaningful cognitive
improvement in phase III clinical trials, threatening the validity of the amyloid

hypothesis. Therefore, new therapies are urgently needed to treat affected patients
and to prevent, or improve the symptoms of AD.

In the current study, we report that YU102, inhibiting LMP2 subunit selectively

in brain, ameliorates memory dysfunction in Tg2576 independent of Aβ deposition

and tau aggregation. In addition, we demonstrated that YU102 blocks activation of
astrocytes and microglia in Tg2576 mice and inhibits LMP2 subunit selectively in BV-

2 microglia cells with high specificity. We also utilized a mouse cytokine array kit and

ELISA assays, measuring the levels of pro-inflammatory cytokines and chemokines
response following LPS-induced microglial activation in cells. Our data showed that
YU102 suppresses the production of IL-1α, IL-1β, IL-6, and CCL12 in microglial cells,

which are important factors involved in the progression of neuroinflammatory
disease, indicating LMP2 inhibition can exhibit anti-neuroinflammatory activity in

vitro by attenuating the production of pro-inflammatory cytokines and chemokines.
This result was particularly surprising given previous reports demonstrating that

LMP2-selective inhibitors have no effect on pro-inflammatory cytokine production
25 or NF-kB activation in human PBMCs or cancers [56, 295]. In microglial BV-2 cells,

the potent LMP7-selective inhibitor ONX 0914 appears to be nearly as effective in

suppressing pro-inflammatory cytokine production as YU102. At the same time, ONX
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0914 was much more cytotoxic than YU102 in all tested cell lines. Overall, it seems
that LMP2 may offer a better therapeutic target than LMP7 for the development of
drugs to treat neurodegenerative diseases.

Several studies have shown that Aβ deposition was detected in the retinas,

which might be responsible for the pathogenesis of AMD by causing RPE

degeneration from different AD transgenic mouse models, resulting in both functional
and structural retinal abnormalities [319, 326-330]. In this study, we also observed
RPE damage in eyes isolated from Tg2576 mice and found YU102 protected from

blocking RPE degeneration. This was further verified by the effect of YU102 on RPE
degeneration in human ARPE-19 cells. We found YU102 suppressed TNF-α-induced
EMT induction, suggesting YU102 may alter signaling pathways which mediate TNFα-induced EMT such as TGF-β signaling pathway [331].

In summary, we showed that YU102, a LMP2-selective inhibitor, improves

cognitive dysfunctions in AD mouse models without affecting Aβ deposition and tau
polymerization. In addition, we found that YU102 suppresses production of proinflammatory cytokines in microglial cells, revealing a previously unrecognized role

of LMP2 in microglia-mediated innate immune responses. Finally, the present study

demonstrated that inhibition of LMP2 possesses anti-neuroinflammatory properties

that suppress microglial activation and represents a potential therapeutic target for
neuroinflammatory diseases such as AD and AMD.
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CHAPTER 6. SUMMARY

Therapeutic agents targeting specific molecular lesions in cancer cells have

substantially improved the survival of cancer patients. But, the inevitable emergence
of drug-resistance presents a formidable challenge for clinicians. Currently, there are

no available strategies in the clinic to combat PI-resistance due to a lack of knowledge
regarding the PI response mechanisms. In order to address this problem, extensive
effort has been put forth over the last decade toward improving our understanding of

the mechanisms responsible for PI resistance. Although several mechanisms of PI
resistance have been proposed previously, these mechanisms have not been
validated clinically and cannot explain all PI resistance observed. Recently, several
studies have shown that UPS-targeting inhibitors including PIs other than Btz retain

anticancer activity in Btz-resistant MM cells, indicating that the UPS remains essential
in these cells and alternative PIs can overcome Btz resistance. However, mechanistic

understanding of intrinsic Cfz resistance is limited due to a lack of suitable cell-based
models.

To elucidate intrinsic Cfz resistance in cancer cells, we identified that H727

human bronchial carcinoid cells are inherently resistant to Cfz and utilized this cell

line to test our hypothesis. We found that proteasome function remained vital to the
survival of Cfz-resistant cancer cells, and that targeting the proteasome using

alternative PIs is a good strategy to overcome Cfz resistance. Additionally, results

obtained from alterations in the composition of proteasome catalytic subunits in the
cell line model showed a potential link may exist between the composition of

proteasome catalytic subunits and the cellular response to Cfz. These findings
support that proteasome catalytic subunit composition may play a major role in

differential responses to PIs among MM patients. Thus, it is crucial to determine
composition of proteasome subunits in cancer cells with intrinsic/acquired PI

resistance to design a new effective treatment for MM patients who do not respond
or have developed resistance to PIs. In addition, this study demonstrates that

proteasome inhibition by alternative PIs may still be a valid therapeutic strategy for
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patients with relapsed MM after having received treatment with Cfz. Although we
believe that cell line model studies provide solid proof of concept evidence for the use

of PIs in Cfz-resistant cells, it will be important to validate these findings using clinical
samples.

Our studies may provide important insights into the design and further

optimization of PIs with improved potency in Cfz-resistant cells. With this in mind,
we designed and synthesized novel epoxyketone-based PIs by structural

modifications at the P1′ site. We observed that a Cfz analog, harboring a hydroxyl

substituent at its P1′ position, was highly cytotoxic against de novo or acquired Cfz
resistant cell lines. These findings support that peptide epoxyketones incorporating
P1′-targeting moieties may have the potential to bypass resistance mechanisms

associated with Cfz and to provide additional clinical options for patients resistant to
Cfz. Moving forward, further studies regarding the efficacy of peptide epoxyketones

incorporating P1′-targeting moieties should be investigated in animal models and
ultimately in clinically-relevant primary cells derived from patient who do not
respond to PI therapies.

Despite extensive efforts to develop therapies for neurodegenerative diseases such

as AD and AMD, effective treatments are not yet available. As such, there is an urgent
need to reshape the drug target landscape and develop therapies against these

diseases. In recent years, dysregulated immune response in the CNS has garnered
increased attention as a target of neurodegenerative diseases. The IP, understood to

contribute to and regulate immune response, has only recently become targetable by
selective inhibitors. While inhibitors targeting the IP catalytic subunit LMP7 are

currently being investigated in preclinical and clinical models of multiple
inflammatory diseases, their efficacy in neurodegenerative diseases has never been

evaluated. Although the IP found to be highly expressed in microglial cells from AD
patients and mouse models, the exact role of IP in AD pathology remains poorly
understood to date.

147

To address the role of IP in AD, we investigated the impact of IP inhibition on

cognitive function in AD mouse models and observed that YU102, a selective inhibitor

of IP catalytic subunit LMP2, is highly effective in improving cognitive behavior of AD
mice without affecting Aβ deposits or tau polymerization, strongly warranting further

investigation of LMP2 inhibition in clinical settings as a new strategy for AD therapy.
Considering the success of YU102 in improving the treatment of AD, we believe that

any effort to identify AD drug candidates will extend from the exciting preliminary
results obtained using YU102 to clinical trials. Thus, further medicinal chemistry

efforts by our group have been yielding a library of structurally unique and diversified

compounds. Our current compound, YU102, is quite promising in terms of the
potency in inhibiting LMP2 and acceptable target selectivity. Thus, our optimization
effort will focus on improving not just the potency and specificity, but also
pharmaceutical properties. We now aim to develop most promising YU102 analogs

(acyclic and macrocyclic) based on the potency, target selectivity and chemical
stability. In addition, further optimization of YU102 will be necessary to BBB

permeability. As well, in vivo efficacy and PK properties will move into the next
phases of AD drug development.
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